US11439642B2 - Substituted 5-fluoro-1H-pyrazolopyridines and their use - Google Patents
Substituted 5-fluoro-1H-pyrazolopyridines and their use Download PDFInfo
- Publication number
- US11439642B2 US11439642B2 US16/919,385 US202016919385A US11439642B2 US 11439642 B2 US11439642 B2 US 11439642B2 US 202016919385 A US202016919385 A US 202016919385A US 11439642 B2 US11439642 B2 US 11439642B2
- Authority
- US
- United States
- Prior art keywords
- compound
- treating
- formula
- inhibitors
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- QZFHIXARHDBPBY-UHFFFAOYSA-N COC(=O)Nc1c(N)nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc1N Chemical compound COC(=O)Nc1c(N)nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc1N QZFHIXARHDBPBY-UHFFFAOYSA-N 0.000 description 15
- QGHFTIKMLOOOSM-UHFFFAOYSA-N Fc1cnc2c(c1)c(I)nn2Cc1ccccc1F Chemical compound Fc1cnc2c(c1)c(I)nn2Cc1ccccc1F QGHFTIKMLOOOSM-UHFFFAOYSA-N 0.000 description 3
- 0 [1*]N(C(=O)OC)c1c(N)nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc1N Chemical compound [1*]N(C(=O)OC)c1c(N)nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc1N 0.000 description 3
- SUBZTZVHVGYOPM-UHFFFAOYSA-N N#Cc1cc(F)cnc1Cl Chemical compound N#Cc1cc(F)cnc1Cl SUBZTZVHVGYOPM-UHFFFAOYSA-N 0.000 description 2
- GPEUANAWZCBBHU-UHFFFAOYSA-N N#Cc1nn(Cc2ccccc2F)c2ncc(F)cc12 Chemical compound N#Cc1nn(Cc2ccccc2F)c2ncc(F)cc12 GPEUANAWZCBBHU-UHFFFAOYSA-N 0.000 description 2
- QHNLOUKOONWPRR-UHFFFAOYSA-N N=C(N)c1nn(Cc2ccccc2F)c2ncc(F)cc12 Chemical compound N=C(N)c1nn(Cc2ccccc2F)c2ncc(F)cc12 QHNLOUKOONWPRR-UHFFFAOYSA-N 0.000 description 2
- FGVPZKOMCCRZTI-QNEJGDQOSA-N Nc1nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc(N)c1/N=N/c1ccccc1 Chemical compound Nc1nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc(N)c1/N=N/c1ccccc1 FGVPZKOMCCRZTI-QNEJGDQOSA-N 0.000 description 2
- DVTLORLSDKRODH-UHFFFAOYSA-N Nc1nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc(N)c1N Chemical compound Nc1nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc(N)c1N DVTLORLSDKRODH-UHFFFAOYSA-N 0.000 description 2
- UVLOQUNYRUZILK-UHFFFAOYSA-N Nc1nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc(N)c1[N+](=O)[O-] Chemical compound Nc1nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc(N)c1[N+](=O)[O-] UVLOQUNYRUZILK-UHFFFAOYSA-N 0.000 description 2
- AMPFRANDCORIRL-UHFFFAOYSA-N CC1=NCc2ncc(F)cc21 Chemical compound CC1=NCc2ncc(F)cc21 AMPFRANDCORIRL-UHFFFAOYSA-N 0.000 description 1
- VCLMEBXZBAMTDK-UHFFFAOYSA-N COC(=O)N(C)c1c(N)nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc1N Chemical compound COC(=O)N(C)c1c(N)nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc1N VCLMEBXZBAMTDK-UHFFFAOYSA-N 0.000 description 1
- HDKHNAIVGQMAAS-UHFFFAOYSA-N COC(=O)N(C)c1c(N)nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc1N.COC(=O)Nc1c(N)nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc1N Chemical compound COC(=O)N(C)c1c(N)nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc1N.COC(=O)Nc1c(N)nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc1N HDKHNAIVGQMAAS-UHFFFAOYSA-N 0.000 description 1
- YGNKMTLKOLHLNE-UHFFFAOYSA-N COC(=O)N(CC(F)(F)F)c1c(N)nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc1N Chemical compound COC(=O)N(CC(F)(F)F)c1c(N)nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc1N YGNKMTLKOLHLNE-UHFFFAOYSA-N 0.000 description 1
- YHXUSBVXODSSJM-UHFFFAOYSA-N COC(=O)Nc1c(N)nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc1N.Fc1cnc2c(c1)c(I)nn2Cc1ccccc1F.Nc1nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc(N)c1N.Nc1nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc(N)c1[N+](=O)[O-].Nc1nc(Cl)nc(N)c1[N+](=O)[O-] Chemical compound COC(=O)Nc1c(N)nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc1N.Fc1cnc2c(c1)c(I)nn2Cc1ccccc1F.Nc1nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc(N)c1N.Nc1nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc(N)c1[N+](=O)[O-].Nc1nc(Cl)nc(N)c1[N+](=O)[O-] YHXUSBVXODSSJM-UHFFFAOYSA-N 0.000 description 1
- XZUGEOHIDXRTAS-UHFFFAOYSA-N COC(=O)Nc1c(N)nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc1N.O=S(=O)(O)CCS(=O)(=O)O Chemical compound COC(=O)Nc1c(N)nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc1N.O=S(=O)(O)CCS(=O)(=O)O XZUGEOHIDXRTAS-UHFFFAOYSA-N 0.000 description 1
- ZBYYVBFAHVINCE-UHFFFAOYSA-N Cc1nc(Cl)nc(N)c1[N+](=O)[O-] Chemical compound Cc1nc(Cl)nc(N)c1[N+](=O)[O-] ZBYYVBFAHVINCE-UHFFFAOYSA-N 0.000 description 1
- FFWQLZFIMNTUCZ-UHFFFAOYSA-N Fc1ccccc1CBr Chemical compound Fc1ccccc1CBr FFWQLZFIMNTUCZ-UHFFFAOYSA-N 0.000 description 1
- SKGPKXOWCGPCBE-UHFFFAOYSA-N Fc1cnc2[nH]cc(I)c2c1 Chemical compound Fc1cnc2[nH]cc(I)c2c1 SKGPKXOWCGPCBE-UHFFFAOYSA-N 0.000 description 1
- HSJHOTUQSLQXLL-UHFFFAOYSA-N Fc1cnc2[nH]nc(I)c2c1 Chemical compound Fc1cnc2[nH]nc(I)c2c1 HSJHOTUQSLQXLL-UHFFFAOYSA-N 0.000 description 1
- UNFSBIZNZKZCBC-UHFFFAOYSA-N Fc1cnc2c(c1)C(I)=NC2 Chemical compound Fc1cnc2c(c1)C(I)=NC2 UNFSBIZNZKZCBC-UHFFFAOYSA-N 0.000 description 1
- UDKPRLWBJFZNRL-UHFFFAOYSA-N Fc1cnc2c(c1)C(I)=NC2.Fc1cnc2c(c1)c(I)nn2Cc1ccccc1F.N#Cc1cc(F)cnc1Cl.NC1=NCc2ncc(F)cc21 Chemical compound Fc1cnc2c(c1)C(I)=NC2.Fc1cnc2c(c1)c(I)nn2Cc1ccccc1F.N#Cc1cc(F)cnc1Cl.NC1=NCc2ncc(F)cc21 UDKPRLWBJFZNRL-UHFFFAOYSA-N 0.000 description 1
- DDNRFAUMLDUJGS-CTGLMZJLSA-N Fc1cnc2c(c1)c(I)nn2Cc1ccccc1F.N#Cc1nn(Cc2ccccc2F)c2ncc(F)cc12.N=C(N)c1nn(Cc2ccccc2F)c2ncc(F)cc12.Nc1nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc(N)c1/N=N/c1ccccc1.Nc1nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc(N)c1N.[C-]#[N+]C(/N=N/c1ccccc1)[N+]#[C-] Chemical compound Fc1cnc2c(c1)c(I)nn2Cc1ccccc1F.N#Cc1nn(Cc2ccccc2F)c2ncc(F)cc12.N=C(N)c1nn(Cc2ccccc2F)c2ncc(F)cc12.Nc1nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc(N)c1/N=N/c1ccccc1.Nc1nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc(N)c1N.[C-]#[N+]C(/N=N/c1ccccc1)[N+]#[C-] DDNRFAUMLDUJGS-CTGLMZJLSA-N 0.000 description 1
- OGXRORGCEDVOCN-UHFFFAOYSA-N N#Cc1cc(F)c(Cl)nc1Cl.N#Cc1cc(F)cnc1Cl.NC(=O)c1cc(F)c(Cl)nc1Cl.NC(=O)c1cc(F)cnc1Cl Chemical compound N#Cc1cc(F)c(Cl)nc1Cl.N#Cc1cc(F)cnc1Cl.NC(=O)c1cc(F)c(Cl)nc1Cl.NC(=O)c1cc(F)cnc1Cl OGXRORGCEDVOCN-UHFFFAOYSA-N 0.000 description 1
- ZVYNUGSPFZCYEV-UHFFFAOYSA-N NC(=O)c1cc(F)c(Cl)nc1Cl Chemical compound NC(=O)c1cc(F)c(Cl)nc1Cl ZVYNUGSPFZCYEV-UHFFFAOYSA-N 0.000 description 1
- KHRZSLCUROLAAR-UHFFFAOYSA-N NC(=O)c1cc(F)cnc1Cl Chemical compound NC(=O)c1cc(F)cnc1Cl KHRZSLCUROLAAR-UHFFFAOYSA-N 0.000 description 1
- UFONWAPOQPJJLL-UHFFFAOYSA-N Nc1n[nH]c2ncc(F)cc12 Chemical compound Nc1n[nH]c2ncc(F)cc12 UFONWAPOQPJJLL-UHFFFAOYSA-N 0.000 description 1
- OFUQVQPOPRAGHK-OUKQBFOZSA-N [C-]#[N+]C(C#N)/N=N/c1ccccc1 Chemical compound [C-]#[N+]C(C#N)/N=N/c1ccccc1 OFUQVQPOPRAGHK-OUKQBFOZSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/05—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing at least two sulfo groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Definitions
- the present application relates to novel substituted 5-fluoro-1H-pyrazolopyridines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.
- cyclic guanosine monophosphate cGMP
- NO nitrogen monoxide
- GTP guanosine triphosphate
- the soluble guanylate cyclases consist of two subunits and very probably contain one haem per heterodimer, which is part of the regulatory site. It is of central importance for the activation mechanism. NO is able to bind to the iron atom of haem and thus markedly increase the activity of the enzyme. Haem-free preparations cannot, by contrast, be stimulated by NO. Carbon monoxide (CO) is also able to attach to the central iron atom of haem, but the stimulation by CO is distinctly less than that by NO.
- CO Carbon monoxide
- guanylate cyclase plays an important role in various physiological processes, in particular in the relaxation and proliferation of smooth muscle cells, in platelet aggregation and platelet adhesion and in neuronal signal transmission, and also in disorders which are based on a disturbance of the abovementioned processes.
- the NO/cGMP system may be suppressed, which may lead for example to high blood pressure, platelet activation, increased cellular proliferation, endothelial dysfunction, atherosclerosis, angina pectoris, heart failure, myocardial infarction, thromboses, stroke and sexual dysfunction.
- WO 00/06569 discloses fused pyrazole derivatives and WO 03/095451 carbamate-substituted 3-pyrimidinylyrazolopyridines as stimulators of soluble guanylate cyclase.
- the present invention provides compounds of the general formula (I)
- Compounds according to the invention are the compounds of the formula (I) and the N-oxides, salts, solvates and solvates of the N-oxides and salts thereof, the compounds, encompassed by formula (I), of the formulae specified hereinafter and the N-oxides, salts, solvates and solvates of the N-oxides and salts thereof, and the compounds encompassed by formula (I) and specified hereinafter as working examples and the N-oxides, salts, solvates and solvates of the N-oxides and salts thereof, to the extent that the compounds encompassed by formula (I) and specified hereinafter are not already N-oxides, salts, solvates and solvates of the N-oxides and salts.
- preferred salts are physiologically acceptable salts of the compounds according to the invention. Also encompassed are salts which are not themselves suitable for pharmaceutical applications but can be used, for example, for isolation or purification of the compounds according to the invention.
- Physiologically acceptable salts of the compounds according to the invention include acid addition salts of mineral acids, carboxylic acids and sulphonic acids, for example salts of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, ethanesulphonic acid, toluenesulphonic acid, benzenesulphonic acid, naphthalenedisulphonic acid, formic acid, acetic acid, trifluoroacetic acid, propionic acid, lactic acid, tartaric acid, malic acid, citric acid, fumaric acid, maleic acid and benzoic acid.
- Physiologically acceptable salts of the compounds according to the invention also include salts of conventional bases, by way of example and with preference alkali metal salts (e.g. sodium and potassium salts), alkaline earth metal salts (e.g. calcium and magnesium salts) and ammonium salts derived from ammonia or organic amines having 1 to 16 carbon atoms, by way of example and with preference ethylamine, diethylamine, triethylamine, ethyldiisopropylamine, monoethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, dimethylaminoethanol, procaine, dibenzylamine, N-methylmorpholine, arginine, lysine, ethylenediamine and N-methylpiperidine.
- alkali metal salts e.g. sodium and potassium salts
- alkaline earth metal salts e.g. calcium and magnesium salts
- ammonium salts derived from ammonia or organic amines
- solvates refer to those forms of the compounds according to the invention which, in the solid or liquid state, form a complex by coordination with solvent molecules. Hydrates are a specific form of the solvates in which the coordination is with water. Preferred solvates in the context of the present invention are hydrates.
- the compounds according to the invention may exist in different stereoisomeric forms, i.e. in the form of configurational isomers or if appropriate also as conformational isomers (enantiomers and/or diastereomers, including those in the case of atropisomers).
- the present invention therefore encompasses the enantiomers or diastereomers and the respective mixtures thereof.
- the stereoisomerically uniform constituents can be isolated from such mixtures of enantiomers and/or diastereomers in a known manner; chromatography processes are preferably used for this, in particular HPLC chromatography on an achiral or chiral phase.
- the present invention also encompasses all suitable isotopic variants of the compounds according to the invention.
- An isotopic variant of a compound according to the invention is understood here to mean a compound in which at least one atom within the compound according to the invention compound has been exchanged for another atom of the same atomic number, but with a different atomic mass than the atomic mass which usually or predominantly occurs in nature.
- isotopes which can be incorporated into a compound according to the invention are those of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulphur, fluorine, chlorine, bromine and iodine, such as 2 H (deuterium), 3 H (tritium), 13 c, 14 C, 15 N, 17 O, 18 O, 32 P, 33 P, 33 S, 34 S, 35 S, 36 S, 18 F, 36 Cl, 82 Br, 123 I, 124 I, 129 I and 131 I.
- Particular isotopic variants of a compound according to the invention may be beneficial, for example, for the examination of the mechanism of action or of the active compound distribution in the body; due to comparatively easy preparability and detectability, especially compounds labelled with 3 H or 14 C isotopes are suitable for this purpose.
- the incorporation of isotopes, for example of deuterium can lead to particular therapeutic benefits as a consequence of greater metabolic stability of the compound, for example an extension of the half-life in the body or a reduction in the active dose required; such modifications of the compounds according to the invention may therefore in some cases also constitute a preferred embodiment of the present invention.
- Isotopic variants of the compounds according to the invention can be prepared by processes known to those skilled in the art, for example by the methods described below and the methods described in the working examples, by using corresponding isotopic modifications of the particular reagents and/or starting compounds therein.
- the present invention also encompasses prodrugs of the compounds according to the invention.
- prodrugs refers to compounds which for their part can be biologically active or inactive, but are converted (for example metabolically or hydrolytically) into compounds according to the invention during their dwell time in the body.
- alkyl represents a straight-chain or branched alkyl radical having 1 to 4 carbon atoms.
- the following may be mentioned by way of example and by way of preference: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 1-methylpropyl, tert-butyl.
- halogen represents fluorine, chlorine, bromine and iodine.
- radicals in the compounds according to the invention are substituted, the radicals may be mono- or polysubstituted, unless specified otherwise.
- all radicals which occur more than once are defined independently of one another. Substitution by one, two or three identical or different substituents is preferred.
- methyl may be substituted by a trifluoromethyl substituent, and their salts, solvates and solvates of the salts.
- the invention further provides a process for preparing the compounds of the formula (I) according to the invention, characterized in that the compound of the formula (II)
- Inert solvents for process step (II)+(III) ⁇ (IV) are, for example, alcohols such as methanol, ethanol, n-propanol, isopropanol, n-butanol or tert-butanol, ethers such as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether, hydrocarbons such as benzene, xylene, toluene, hexane, cyclohexane or mineral oil fractions, or other solvents such as dimethylformamide (DMF), dimethyl sulphoxide (DMSO), N,N′-dimethylpropyleneurea (DMPU), dimethylacetamide, N-methylpyrrolidone (NMP), pyridine, acetonitrile, sulpholane or else water. It is equally possible to use mixtures of the solvents mentioned. Preference is given to dioxan
- Suitable palladium catalysts for process step (II)+(III) ⁇ (IV) are, for example, palladium on activated carbon, palladium(II) acetate, tetrakis(triphenylphosphine)palladium(0), bis(triphenylphosphine)palladium(II) chloride, bis(acetonitrile)palladium(II) chloride and [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II)/dichloromethane complex, if appropriate in combination with additional phosphane ligands such as, for example, (2-biphenyl)di-tert-butylphosphine, dicyclohexyl[2′,4′,6′-tris(1-methylethyl)biphenyl-2-yl]phosphane (XPHOS), bis(2-phenylphosphinophenyl) ether
- the reaction (II)+(III) ⁇ (IV) is generally carried out in a temperature range of from +20° C. to +180° C., prepferably from +50° C. to +120° C., if appropriate in a microwave.
- the reaction can be carried out at atmospheric, elevated or reduced pressure (for example from 0.5 to 5 bar).
- the reaction is generally carried out at atmospheric pressure.
- the reductions (IV) ⁇ (V) and (IX) ⁇ (V) are carried out in the presence of a suitable catalyst in an inert solvent in a temperature range of from +20° C. to +40° C. under hydrogen of atmospheric pressure.
- Inert solvents for the reductions (IV) ⁇ (V) and (IX) ⁇ (V) are, for example, alcohols such as methanol, ethanol, n-propanol, isopropanol, n-butanol or tert-butanol, ethers such as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether, or other solvents such as dimethylformamide (DMF), dimethyl sulphoxide (DMSO), N,N′-dimethylpropyleneurea (DMPU), N-methylpyrrolidone (NMP), pyridine, acetonitrile or else water. It is equally possible to use mixtures of the solvents mentioned. Preference is given to DMF and pyridine.
- Suitable catalysts for the reactions (IV) ⁇ (V) and (IX) ⁇ (V) are, for example, palladium on activated carbon, platinum on carbon, palladium hydroxide or Raney nickel.
- the reductions (IV) ⁇ (V) and (IX) ⁇ (V) can be carried out using a metal or metal salt such as, for example, iron, zinc or tin(II) chloride in a suitable acid such as, for example, hydrogen chloride/hydrochloric acid, sulphuric acid, phosphoric acid or acetic acid in a temperature range of from +20° C. to +140° C.
- a metal or metal salt such as, for example, iron, zinc or tin(II) chloride in a suitable acid such as, for example, hydrogen chloride/hydrochloric acid, sulphuric acid, phosphoric acid or acetic acid in a temperature range of from +20° C. to +140° C.
- Inert solvents for process step (V) ⁇ (I-A) are, for example, alcohols such as methanol, ethanol, n-propanol, isopropanol, n-butanol or tert-butanol, ethers such as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether, halogenated hydrocarbons such as dichloromethane, trichloromethane, carbon tetrachloride, trichloroethylene or chlorobenzene, hydrocarbons such as benzene, xylene, toluene, hexane, cyclohexane or mineral oil fractions, or other solvents such as dimethylformamide (DMF), dimethyl sulphoxide (DMSO), N,N′-dimethylpropyleneurea (DMPU), N-methylpyrrolidone (NMP), acetonitrile or
- Suitable bases for the process step (V) ⁇ (I-A) are alkali metal hydrides such as sodium hydride, alkali metal hydroxides such as, for example, lithium hydroxide, sodium hydroxide or potassium hydroxide, alkali metal carbonates such as lithium carbonate, sodium carbonate, potassium carbonate or caesium carbonate, alkali metal bicarbonates such as sodium bicarbonate or potassium bicarbonate, alkali metal alkoxides such as sodium methoxide or potassium methoxide, sodium ethoxide or potassium ethoxide or potassium tert-butoxide, or organic amines such as triethylamine, diisopropylethylamine, pyridine, 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) or 1,5-diazabicyclo[4.3.0]non-5-ene (DBN). Preference is given to pyridine.
- alkali metal hydrides such as sodium hydride
- the reaction (V) ⁇ (I-A) is generally carried out in a temperature range of from ⁇ 10° C. to +30° C., preferably from 0° C. to +20° C.
- the reaction can be carried out at atmospheric, elevated or reduced pressure (for example from 0.5 to 5 bar).
- the reaction is generally carried out at atmospheric pressure.
- Inert solvents for process step (II) ⁇ (VI) are, for example, ethers such as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether, hydrocarbons such as benzene, xylene, toluene, hexane, cyclohexane or mineral oil fractions, or other solvents such as dimethylformamide (DMF), dimethyl sulphoxide (DMSO), N,N′-dimethylpropyleneurea (DMPU), N-methylpyrrolidone (NMP), pyridine or acetonitrile. It is equally possible to use mixtures of the solvents mentioned. Preference is given to DMSO.
- the reaction (II) ⁇ (VI) is generally carried out in a temperature range of from +20° C. to +180° C., preferably from +100° C. to +160° C., if appropriate in a microwave.
- the reaction can be carried out at atmospheric, elevated or reduced pressure (for example from 0.5 to 5 bar).
- the reaction is generally carried out at atmospheric pressure.
- reaction (VI) ⁇ (VII) is carried out using methods known to the person skilled in the art in a two-step process initially with formation of the imino ester using sodium methoxide in methanol at from 0° C. to +40° C. and subsequent nucleophilic addition of an ammonia equivalent such as, for example, ammonia or ammonium chloride in acetic acid with formation of the amidine (VII) at from +50 to +150° C.
- an ammonia equivalent such as, for example, ammonia or ammonium chloride in acetic acid
- Inert solvents for process step (VII)+(VIII) ⁇ (IX) are alcohols such as methanol, ethanol, n-propanol, isopropanol, n-butanol or tert-butanol, ethers such as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether, hydrocarbons such as benzene, xylene, toluene, hexane, cyclohexane or mineral oil fractions, or other solvents such as dimethylformamide (DMF), dimethyl sulphoxide (DMSO), N,N′-dimethylpropyleneurea (DMPU), N-methylpyrrolidone (NMP), pyridine, acetonitrile or else water. It is equally possible to use mixtures of the solvents mentioned. Preference is given to DMF.
- Suitable bases for the process step (VII)+(VIII) ⁇ (IX) are alkali metal hydroxides such as, for example, lithium hydroxide, sodium hydroxide or potassium hydroxide, alkali metal carbonates such as lithium carbonate, sodium carbonate, potassium carbonate or caesium carbonate, alkali metal bicarbonates such as sodium bicarbonate or potassium bicarbonate, alkali metal alkoxides such as sodium methoxide or potassium methoxide, sodium ethoxide or potassium ethoxide or potassium tert-butoxide, or organic amines such as triethylamine, diisopropylethylamine, pyridine, 1,8-diazabicyclo [5.4.0]undec-7-ene (DBU) or 1,5-diazabicyclo[4.3.0]non-5-ene (DBN). Preference is given to triethylamine.
- alkali metal hydroxides such as, for example, lithium hydroxide, sodium hydrox
- the reaction (VII)+(VIII) ⁇ (IX) is generally carried out in a temperature range of from +20° C. to +150° C., preferably from +80° C. to +120° C., if appropriate in a microwave.
- the reaction can be carried out at atmospheric, elevated or reduced pressure (for example from 0.5 to 5 bar).
- the reaction is generally carried out at atmospheric pressure.
- the compound of the formula (VIII) can be prepared analogously to the literature L. F. Cavalieri, J. F. Tanker, A. Bendich, J. Am. Chem. Soc., 1949, 71, 533.
- Inert solvents for the reaction (I-A) ⁇ (I-B) are, for example, halogenated hydrocarbons such as dichloromethane, trichloromethane, carbon tetrachloride, trichloroethylene or chlorobenzene, ethers such as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether, or other solvents such as dimethylformamide (DMF), dimethyl sulphoxide (DMSO), N,N′-dimethylpropyleneurea (DMPU), N-methylpyrrolidone (NMP), pyridine or acetonitrile. Preference is given to tetrahydrofuran.
- halogenated hydrocarbons such as dichloromethane, trichloromethane, carbon tetrachloride, trichloroethylene or chlorobenzene
- ethers such as diethyl ether, diox
- Suitable bases for the process step (I-A) ⁇ (I-B) are alkali metal hydrides such as potassium hydride or sodium hydride, alkali metal carbonates such as lithium carbonate, sodium carbonate, potassium carbonate or caesium carbonate, alkali metal bicarbonates such as sodium bicarbonate or potassium bicarbonate, alkali metal alkoxides such as sodium methoxide or potassium methoxide, sodium ethoxide or potassium ethoxide or potassium tert-butoxide, amides such as sodium amide, lithium bis(trimethylsilyl)amide, sodium bis(trimethylsilyl)amide or potassium bis(trimethylsilyl)amide or lithium diisopropylamide, organometallic compounds such as butyllithium or phenyllithium, or organic amines such as triethylamine, diisopropylethylamine, pyridine, 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU)
- the reaction (I-A) ⁇ (I-B) is generally carried out in a temperature range of from ⁇ 78° C. to +40° C., preferably from 0° C. to +20° C.
- the reaction can be carried out at atmospheric, elevated or reduced pressure (for example from 0.5 to 5 bar).
- the reaction is generally carried out at atmospheric pressure.
- the compound of the formula (II) can be prepared by cyclizing the compound of the formula (X)
- Inert solvents for process step (X) ⁇ (XI) are alcohols such as methanol, ethanol, n-propanol, isopropanol, n-butanol, tert-butanol or 1,2-ethanediol, ethers such as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether, hydrocarbons such as benzene, xylene, toluene, hexane, cyclohexane or mineral oil fractions, or other solvents such as dimethylformamide (DMF), dimethyl sulphoxide (DMSO), N,N′-dimethylpropyleneurea (DMPU), N-methylpyrrolidone (NMP), pyridine, acetonitrile or else water. It is equally possible to use mixtures of the solvents mentioned. 1,2-Ethanediol is preferred.
- the reaction (X) ⁇ (XI) is generally carried out in a temperature range of from +60° C. to +200° C., preferably from +120° C. to +180° C.
- the reaction can be carried out at atmospheric, elevated or reduced pressure (for example from 0.5 to 5 bar).
- the reaction is generally carried out at atmospheric pressure.
- Inert solvents for the reaction (XI) ⁇ (XII) are, for example, halogenated hydrocarbons such as dichloromethane, trichloromethane, carbon tetrachloride, trichloroethylene or chlorobenzene, ethers such as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether, or other solvents such as dimethylformamide (DMF), dimethyl sulphoxide (DMSO), N,N′-dimethylpropyleneurea (DMPU), N-methylpyrrolidone (NMP), pyridine or acetonitrile. Preference is given to DMF.
- halogenated hydrocarbons such as dichloromethane, trichloromethane, carbon tetrachloride, trichloroethylene or chlorobenzene
- ethers such as diethyl ether, dioxane, tetra
- Suitable Lewis acids for the process step (XI) ⁇ (XII) are boron trifluoride/diethyl ether complex, cerium(IV) ammonium nitrate (CAN), tin(II) chloride, lithium perchlorate, zinc(II) chloride, indium(III) chloride or indium(III) bromide. Preference is given to boron trifluoride/diethyl ether complex.
- the reaction (XI) ⁇ (XII) is generally carried out in a temperature range of from ⁇ 78° C. to +40° C., preferably from 0° C. to +20° C.
- the reaction can be carried out at atmospheric, elevated or reduced pressure (for example from 0.5 to 5 bar).
- the reaction is generally carried out at atmospheric pressure.
- Inert solvents for the reaction (XII)+(XIII) ⁇ (II) are, for example, halogenated hydrocarbons such as dichloromethane, trichloromethane, carbon tetrachloride, trichloroethylene or chlorobenzene, ethers such as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether, or other solvents such as dimethylformamide (DMF), dimethyl sulphoxide (DMSO), N,N′-dimcthylpropylcncurca (DMPU), N-methylpyrrolidone (NMP), pyridine or acetonitrile. Preference is given to DMF.
- halogenated hydrocarbons such as dichloromethane, trichloromethane, carbon tetrachloride, trichloroethylene or chlorobenzene
- ethers such as diethyl ether,
- Suitable bases for the process step (XII)+(XIII) ⁇ (II) are alkali metal hydrides such as potassium hydride or sodium hydride, alkali metal carbonates such as lithium carbonate, sodium carbonate, potassium carbonate or caesium carbonate, alkali metal bicarbonates such as sodium bicarbonate or potassium bicarbonate, alkali metal alkoxides such as sodium methoxide or potassium methoxide, sodium ethoxide or potassium ethoxide or potassium tert-butoxide, amides such as sodium amide, lithium bis(trimethylsilyl)amide, sodium bis(trimethylsilyl)amide or potassium bis(trimethylsilyl)amide or lithium diisopropylamide, organometallic compounds such as butyllithium or phenyllithium, or organic amines such as triethylamine, diisopropylethylamine, pyridine, 1,8-diazabicyclo[5.4.0]undec-7-ene
- the reaction (XII)+(XIII) ⁇ (II) is generally carried out in a temperature range of from 0° C. to +60° C., preferably from +10° C. to +25° C.
- the reaction can be carried out at atmospheric, elevated or reduced pressure (for example from 0.5 to 5 bar).
- the reaction is generally carried out at atmospheric pressure.
- the present invention furthermore provides the compound:
- the present invention furthermore provides the compound:
- the compound of the formula (X) is known from the literature [cf., for example, Winn M., J. Med. Chem. 1993, 36, 2676-7688; EP 634 413-A1; CN 1613849-A; EP 1626045-A1; WO 2009/018415] and can be prepared in analogy to literature processes or as shown in the synthesis scheme below (Scheme 5):
- the compounds according to the invention act as stimulators of soluble guanylate cyclase and have an identical or improved therapeutic profile compared to compounds known from the prior art, such as, for example, with respect to their in vivo properties such as, for example, their pharmacokinetic and pharmacodynamic behaviour and/or their dose-activity relationship and/or their safety profile. They are therefore suitable for the treatment and/or prophylaxis of diseases in man and animals.
- the compounds according to the invention lead to vasorelaxation, to an inhibition of platelet aggregation and to a reduction in blood pressure, and also to an increase in coronary blood flow. These effects are mediated via direct stimulation of soluble guanylate cyclase and intracellular cGMP increase. Moreover, the compounds according to the invention enhance the effect of substances increasing the cGMP concentration, such as, for example, EDRF (endothelium-derived relaxing factor), NO donors, protoporphyrin IX, arachidonic acid or phenylhydrazine derivatives.
- EDRF endothelium-derived relaxing factor
- the compounds according to the invention are suitable for the treatment and/or prophylaxis of cardiovascular, pulmonary, thromboembolic and fibrotic disorders.
- the compounds according to the invention can be used in medicaments for the treatment and/or prophylaxis of cardiovascular disorders such as, for example, hypertension, acute and chronic heart failure, coronary heart disease, stable and unstable angina pectoris, peripheral and cardiac vascular disorders, arrhythmias, atrial and ventricular arrhythmias and impaired conduction such as, for example, atrioventricular blocks degrees I-III (AB block supraventricular tachyarrhythmia, atrial fibrillation, atrial flutter, ventricular fibrillation, ventricular flutter, ventricular tachyarrhythmia, Torsade de pointes tachycardia, atrial and ventricular extrasystoles, AV-junctional extrasystoles, Sick-Sinus syndrome, syncopes, AV-nodal re-entry tachycardia, Wolff-Parkinson-White syndrome, of acute coronary syndrome (ACS), autoimmune cardiac disorders (pericarditis, endocarditis, end
- heart failure also includes more specific or related types of disease, such as acute decompensated heart failure, right heart failure, left heart failure, global failure, ischaemic cardiomyopathy, dilated cardiomyopathy, hypertrophic cardiomyopathy, idiopathic cardiomyopathy, congenital heart defects, heart valve defects, heart failure associated with heart valve defects, mitral stenosis, mitral insufficiency, aortic stenosis, aortic insufficiency, tricuspid stenosis, tricuspid insufficiency, pulmonary valve stenosis, pulmonary valve insufficiency, combined heart valve defects, myocardial inflammation (myocarditis), chronic myocarditis, acute myocarditis, viral myocarditis, diabetic heart failure, alcoholic cardiomyopathy, cardiac storage disorders, and diastolic and systolic heart failure.
- myocardial inflammation myocarditis
- chronic myocarditis chronic myocarditis
- the compounds according to the invention can also be used for the treatment and/or prophylaxis of arteriosclerosis, impaired lipid metabolism, hypolipoproteinaemias, dyslipidaemias, hypertriglyceridaemias, hyperlipidaemias, hypercholesterolaemias, abetalipoproteinaemias, sitosterolaemia, xanthomatosis, Tangier disease, adipositas, obesity and of combined hyperlipidaemias and metabolic syndrome.
- the compounds according to the invention can additionally be used for the treatment and/or prophylaxis of primary and secondary Raynaud's phenomenon, of microcirculation impairments, claudication, peripheral and autonomic neuropathies, diabetic microangiopathies, diabetic retinopathy, diabetic ulcers on the extremities, gangrene, CREST syndrome, erythematosis, onychomycosis, rheumatic disorders and for promoting wound healing.
- the compounds according to the invention are furthermore suitable for treating urological disorders such as, for example, benign prostate syndrome (BPS), benign prostate hyperplasia (BPH), benign prostate enlargement (BPE), bladder outlet obstruction (BOO), lower urinary tract syndromes (LUTS, including Feline Urological Syndrome (FUS)), disorders of the urogenital system including neurogenic over-active bladder (OAB) and (IC), incontinence (UI) such as, for example, mixed urinary incontinence, urge urinary incontinence, stress urinary incontinence or overflow urinary incontinence (MUI, UUI, SUI, OUI), pelvic pain, benign and malignant disorders of the organs of the male and female urogenital system.
- BPS benign prostate syndrome
- BPH benign prostate hyperplasia
- BPE benign prostate enlargement
- BOO bladder outlet obstruction
- LUTS lower urinary tract syndromes
- LUTS lower urinary tract syndromes
- FUS Feline Urological Syndrome
- UI incontinence
- kidney disorders in particular of acute and chronic renal insufficiency and acute and chronic renal failure.
- renal insufficiency comprises both acute and chronic manifestations thereof, as well as underlying or related kidney diseases such as renal hypoperfusion, intradialytic hypotension, obstructive uropathy, glomerulopathies, glomerulonephritis, acute glomerulonephritis, glomerulosclerosis, tubulointerstitial diseases, nephropathic diseases such as primary and congenital kidney disease, nephritis, immunological kidney diseases such as kidney graft rejection and immunocomplex-induced kidney diseases, nephropathy induced by toxic substances, nephropathy induced by contrast agents, diabetic and non-diabetic nephropathy, pyelonephritis, renal cysts, nephrosclerosis, hypertensive nephrosclerosis
- the present invention also comprises the use of the compounds according to the invention for the treatment and/or prophylaxis of sequelae of renal insufficiency, for example pulmonary oedema, heart failure, uraemia, anaemia, electrolyte disturbances (for example hypercalaemia, hyponatraemia) and disturbances in bone and carbohydrate metabolism.
- sequelae of renal insufficiency for example pulmonary oedema, heart failure, uraemia, anaemia, electrolyte disturbances (for example hypercalaemia, hyponatraemia) and disturbances in bone and carbohydrate metabolism.
- the compounds according to the invention are also suitable for the treatment and/or prophylaxis of asthmatic disorders, pulmonary arterial hypertension (PAH) and other forms of pulmonary hypertension (PH) including left-heart disease, HIV, sickle cell anaemia, thromboembolisms (CTEPH), sarkoidosis, COPD or pulmonary fibrosis-associated pulmonary hypertension, chronic-obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), acute lung injury (ALI), alpha-1-antitrypsin deficiency (AATD), pulmonary fibrosis, pulmonary emphysema (for example pulmonary emphysema induced by cigarette smoke) and cystic fibrosis (CF).
- PAH pulmonary arterial hypertension
- PH pulmonary hypertension
- COPD chronic-obstructive pulmonary disease
- ARDS acute respiratory distress syndrome
- ALI acute lung injury
- AATD alpha-1-antitrypsin deficiency
- the compounds described in the present invention also represent active compounds for controlling central nervous system diseases characterized by disturbances of the NO/cGMP system. They are suitable in particular for improving perception, concentration, learning or memory after cognitive impairments like those occurring in particular in association with situations/diseases/syndromes such as mild cognitive impairment, age-associated learning and memory impairments, age-associated memory losses, vascular dementia, craniocerebral trauma, stroke, dementia occurring after strokes (post stroke dementia), post-traumatic craniocerebral trauma, general concentration impairments, concentration impairments in children with learning and memory problems, Alzheimer's disease, Lewy body dementia, dementia with degeneration of the frontal lobes including Pick's syndrome, Parkinson's disease, progressive nuclear palsy, dementia with corticobasal degeneration, amyolateral sclerosis (ALS), Huntington's disease, demyelination, multiple sclerosis, thalamic degeneration, Creutzfeld-Jacob dementia, HIV dementia, schizophrenia with dementia or Korsakoff's psychosis.
- the compounds according to the invention are furthermore also suitable for controlling cerebral blood flow and thus represent effective agents for controlling migraine. They are also suitable for the prophylaxis and control of sequelae of cerebral infarct (Apoplexia cerebri) such as stroke, cerebral ischaemias and skull-brain trauma.
- the compounds according to the invention can likewise be employed for controlling states of pain and tinnitus.
- the compounds according to the invention have antiinflammatory action and can therefore be used as antiinflammatory agents for the treatment and/or prophylaxis of sepsis (SIRS), multiple organ failure (MODS, MOF), inflammatory disorders of the kidney, chronic intestinal inflammations (IBD, Crohn's disease, UC), pancreatitis, peritonitis, rheumatoid disorders, inflammatory skin diseases and inflammatory eye diseases.
- SIRS sepsis
- MODS multiple organ failure
- IBD chronic intestinal inflammations
- Crohn's disease UC
- pancreatitis peritonitis
- rheumatoid disorders inflammatory skin diseases and inflammatory eye diseases.
- the compounds according to the invention can also be used for the treatment and/or prophylaxis of autoimmune diseases.
- the compounds according to the invention are furthermore suitable for the treatment and/or prophylaxis of fibrotic disorders of the internal organs such as, for example, the lung, the heart, the kidney, the bone marrow and in particular the liver, and also dermatological fibroses and fibrotic eye disorders.
- fibrotic disorders includes in particular the following terms: hepatic fibrosis, cirrhosis of the liver, pulmonary fibrosis, endomyocardial fibrosis, nephropathy, glomerulonephritis, interstitial renal fibrosis, fibrotic damage resulting from diabetes, bone marrow fibrosis and similar fibrotic disorders, scleroderma, morphea, keloids, hypertrophic scarring (also following surgical procedures), naevi, diabetic retinopathy, proliferative vitreoretinopathy and disorders of the connective tissue (for example sarcoidosis).
- the compounds according to the invention are furthermore suitable for controlling postoperative scarring, for example as a result of glaucoma operations.
- the compounds according to the invention can also be used cosmetically for ageing and keratinized skin.
- the compounds according to the invention are suitable for the treatment and/or prophylaxis of hepatitis, neoplasms, osteoporosis, glaucoma and gastroparesis.
- the present invention further provides for the use of the compounds according to the invention for the treatment and/or prophylaxis of disorders, in particular the disorders mentioned above.
- the present invention further provides the use of the compounds according to the invention for the treatment and/or prophylaxis of heart failure, angina pectoris, hypertension, pulmonary hypertension, ischaemias, vascular disorders, kidney failure, thromboembolic disorders, fibrotic disorders and arteriosclerosis.
- the present invention further provides the compounds according to the invention for use in a method for the treatment and/or prophylaxis of heart failure, angina pectoris, hypertension, pulmonary hypertension, ischaemias, vascular disorders, kidney failure, thromboembolic disorders, fibrotic disorders and arteriosclerosis.
- the present invention further provides for the use of the compounds according to the invention for producing a medicament for treatment and/or prophylaxis of disorders, in particular the disorders mentioned above.
- the present invention further provides for the use of the compounds according to the invention for producing a medicament for treatment and/or prophylaxis of heart failure, angina pectoris, hypertension, pulmonary hypertension, ischaemias, vascular disorders, kidney failure, thromboembolic disorders, fibrotic disorders and arteriosclerosis.
- the present invention further provides a method for treatment and/or prophylaxis of disorders, in particular the disorders mentioned above, using an effective amount of at least one of the compounds according to the invention.
- the present invention further provides a method for treatment and/or prophylaxis of heart failure, angina pectoris, hypertension, pulmonary hypertension, ischaemias, vascular disorders, kidney failure, thromboembolic disorders, fibrotic disorders and arteriosclerosis using an effective amount of at least one of the compounds according to the invention.
- the compounds according to the invention can be employed alone or, if required, in combination with other active compounds.
- the present invention further provides medicaments comprising at least one of the compounds according to the invention and one or more further active compounds, especially for the treatment and/or prophylaxis of the aforementioned disorders.
- suitable active compound combinations include:
- Agents having antithrombotic activity preferably mean compounds from the group of platelet aggregation inhibitors, of anticoagulants or of profibrinolytic substances.
- the compounds according to the invention are administered in combination with a platelet aggregation inhibitor such as, by way of example and preferably, aspirin, clopidogrel, ticlopidin or dipyridamol.
- a platelet aggregation inhibitor such as, by way of example and preferably, aspirin, clopidogrel, ticlopidin or dipyridamol.
- the compounds according to the invention are administered in combination with a thrombin inhibitor such as, by way of example and preferably, ximelagatran, dabigatran, melagatran, bivalirudin or clexane.
- a thrombin inhibitor such as, by way of example and preferably, ximelagatran, dabigatran, melagatran, bivalirudin or clexane.
- the compounds according to the invention are administered in combination with a GPIIb/IIIa antagonist such as, by way of example and preferably, tirofiban or abciximab.
- a GPIIb/IIIa antagonist such as, by way of example and preferably, tirofiban or abciximab.
- the compounds according to the invention are administered in combination with a factor Xa inhibitor such as, by way of example and preferably, rivaroxab an (BAY 59-7939), DU-176b, apixab an, otamixab an, fidexab an, razaxab an, fondaparinux, idraparinux, PMD-3112, YM-150, KFA-1982, EMD-503982, MCM-17, MLN-1021, DX 9065a, DPC 906, JTV 803, SSR-126512 or SSR-128428.
- a factor Xa inhibitor such as, by way of example and preferably, rivaroxab an (BAY 59-7939), DU-176b, apixab an, otamixab an, fidexab an, razaxab an, fondaparinux, idraparinux, PMD-3112, YM-150, KFA
- the compounds according to the invention are administered in combination with heparin or a low molecular weight (LMW) heparin derivative.
- LMW low molecular weight
- the compounds according to the invention are administered in combination with a vitamin K antagonist such as, by way of example and preferably, coumarin.
- Agents which lower blood pressure are preferably understood to mean compounds from the group of calcium antagonists, angiotensin AII antagonists, ACE inhibitors, endothelin antagonists, renin inhibitors, alpha-receptor blockers, beta-receptor blockers, mineralocorticoid receptor antagonists, and the diuretics.
- the compounds according to the invention are administered in combination with a calcium antagonist such as, by way of example and preferably, nifedipine, amlodipine, verapamil or diltiazem.
- a calcium antagonist such as, by way of example and preferably, nifedipine, amlodipine, verapamil or diltiazem.
- the compounds according to the invention are administered in combination with an alpha-1 receptor blocker such as, by way of example and preferably, prazosin.
- the compounds according to the invention are administered in combination with a beta receptor blocker such as, by way of example and preferably, propranolol, atenolol, timolol, pindolol, alprenolol, oxprenolol, penbutolol, bupranolol, metipranolol, nadolol, mepindolol, carazalol, sotalol, metoprolol, betaxolol, celiprolol, bisoprolol, carteolol, esmolol, labetalol, carvedilol, adaprolol, landiolol, nebivolol, epanolol or bucindolol.
- a beta receptor blocker such as, by way of example and preferably, propranolol, atenolol, timolol, pind
- the compounds according to the invention are administered in combination with an angiotensin AII antagonist such as, by way of example and preferably, losartan, candesartan, valsartan, telmisartan or embusartan.
- angiotensin AII antagonist such as, by way of example and preferably, losartan, candesartan, valsartan, telmisartan or embusartan.
- the compounds according to the invention are administered in combination with an ACE inhibitor such as, by way of example and preferably, enalapril, captopril, lisinopril, ramipril, delapril, fosinopril, quinopril, perindopril or trandopril.
- an ACE inhibitor such as, by way of example and preferably, enalapril, captopril, lisinopril, ramipril, delapril, fosinopril, quinopril, perindopril or trandopril.
- the compounds according to the invention are administered in combination with an endothelin antagonist such as, by way of example and preferably, bosentan, darusentan, ambrisentan or sitaxsentan.
- an endothelin antagonist such as, by way of example and preferably, bosentan, darusentan, ambrisentan or sitaxsentan.
- the compounds according to the invention are administered in combination with a renin inhibitor such as, for example and preferably, aliskiren, SPP-600 or SPP-800.
- a renin inhibitor such as, for example and preferably, aliskiren, SPP-600 or SPP-800.
- the compounds according to the invention are administered in combination with a mineralocorticoid receptor antagonist such as, for example and preferably, spironolactone or eplerenone.
- a mineralocorticoid receptor antagonist such as, for example and preferably, spironolactone or eplerenone.
- the compounds according to the invention are administered in combination with a loop diuretic such as, for example, furosemide, torasemide, bumetanide and piretanide, with potassium-sparing diuretics such as, for example, amiloride and triamterene, with aldosterone antagonists such as, for example, spironolactone, potassium canrenoate and eplerenone and also thiazide diuretics such as, for example, hydrochlorothiazide, chlorthalidone, xipamide and indapamide.
- a loop diuretic such as, for example, furosemide, torasemide, bumetanide and piretanide
- potassium-sparing diuretics such as, for example, amiloride and triamterene
- aldosterone antagonists such as, for example, spironolactone, potassium canrenoate and eplerenone
- thiazide diuretics such as, for
- Active compounds which alter lipid metabolism are preferably understood to mean compounds from the group of CETP inhibitors, thyroid receptor agonists, cholesterol synthesis inhibitors such as HMG-CoA reductase inhibitors or squalene synthesis inhibitors, of ACAT inhibitors, MTP inhibitors, PPAR-alpha, PPAR-gamma and/or PPAR-delta agonists, cholesterol absorption inhibitors, polymeric bile acid adsorbents, bile acid reabsorption inhibitors, lipase inhibitors and lipoprotein(a) antagonists;
- the compounds according to the invention are administered in combination with a CETP inhibitor such as, by way of example and preferably, dalcetrapib, BAY 60-5521, anacetrapib or CETP vaccine (CETi-1).
- a CETP inhibitor such as, by way of example and preferably, dalcetrapib, BAY 60-5521, anacetrapib or CETP vaccine (CETi-1).
- the compounds according to the invention are administered in combination with a thyroid receptor agonist such as, by way of example and preferably, D-thyroxin, 3,5,3′-triiodothyronin (T3), CGS 23425 or axitirome (CGS 26214).
- a thyroid receptor agonist such as, by way of example and preferably, D-thyroxin, 3,5,3′-triiodothyronin (T3), CGS 23425 or axitirome (CGS 26214).
- the compounds according to the invention are administered in combination with a HMG-CoA reductase inhibitor from the class of the statins such as, by way of example and preferably, lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, rosuvastatin or pitavastatin.
- a HMG-CoA reductase inhibitor from the class of the statins such as, by way of example and preferably, lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, rosuvastatin or pitavastatin.
- the compounds according to the invention are administered in combination with a squalene synthesis inhibitor such as, by way of example and preferably, BMS-188494 or TAK-475.
- a squalene synthesis inhibitor such as, by way of example and preferably, BMS-188494 or TAK-475.
- the compounds according to the invention are administered in combination with an ACAT inhibitor such as, by way of example and preferably, avasimibe, melinamide, pactimibe, eflucimibe or SMP-797.
- an ACAT inhibitor such as, by way of example and preferably, avasimibe, melinamide, pactimibe, eflucimibe or SMP-797.
- the compounds according to the invention are administered in combination with an MTP inhibitor such as, by way of example and preferably, implitapide, BMS-201038, R-103757 or JTT-130.
- an MTP inhibitor such as, by way of example and preferably, implitapide, BMS-201038, R-103757 or JTT-130.
- the compounds according to the invention are administered in combination with a PPAR-gamma agonist such as, by way of example and preferably, pioglitazonc or rosiglitazonc.
- a PPAR-gamma agonist such as, by way of example and preferably, pioglitazonc or rosiglitazonc.
- the compounds according to the invention are administered in combination with a PPAR-delta agonist such as, for example and preferably, GW 501516 or BAY 68-5042.
- a PPAR-delta agonist such as, for example and preferably, GW 501516 or BAY 68-5042.
- the compounds according to the invention are administered in combination with a cholesterol absorption inhibitor such as, by way of example and preferably, ezetimibe, tiqueside or pamaqueside.
- a cholesterol absorption inhibitor such as, by way of example and preferably, ezetimibe, tiqueside or pamaqueside.
- the compounds according to the invention are administered in combination with a lipase inhibitor, a preferred example being orlistat.
- the compounds according to the invention are administered in combination with a polymeric bile acid adsorbent such as, by way of example and preferably, cholestyramine, colestipol, colesolvam, CholestaGel or colestimide.
- a polymeric bile acid adsorbent such as, by way of example and preferably, cholestyramine, colestipol, colesolvam, CholestaGel or colestimide.
- the compounds according to the invention are administered in combination with an lipoprotein(a) antagonist such as, by way of example and preferably, gemcabene calcium (CI-1027) or nicotinic acid.
- an lipoprotein(a) antagonist such as, by way of example and preferably, gemcabene calcium (CI-1027) or nicotinic acid.
- the present invention further provides medicaments which comprise at least one compound according to the invention, typically together with one or more inert, nontoxic, pharmaceutically suitable auxiliaries, and the use thereof for the aforementioned purposes.
- the compounds according to the invention may act systemically and/or locally.
- they can be administered in a suitable manner, for example by the oral, parenteral, pulmonal, nasal, sublingual, lingual, buccal, rectal, dermal, transdermal, conjunctival, otic route, or as an implant or stent.
- the compounds according to the invention can be administered in administration forms suitable for these administration routes.
- Suitable administration forms for oral administration are those which work according to the prior art, which release the compounds according to the invention rapidly and/or in a modified manner and which contain the compounds according to the invention in crystalline and/or amorphized and/or dissolved form, for example tablets (uncoated or coated tablets, for example with gastric juice-resistant or retarded-dissolution or insoluble coatings which control the release of the compound according to the invention), tablets or films/wafers which disintegrate rapidly in the oral cavity, films/lyophilizates or capsules (for example hard or soft gelatin capsules), sugar-coated tablets, granules, pellets, powders, emulsions, suspensions, aerosols or solutions.
- tablets uncoated or coated tablets, for example with gastric juice-resistant or retarded-dissolution or insoluble coatings which control the release of the compound according to the invention
- tablets or films/wafers which disintegrate rapidly in the oral cavity
- films/lyophilizates or capsules for example hard or soft gelatin
- Parenteral administration can bypass an absorption step (e.g. intravenously, intraarterially, intracardially, intraspinally or intralumbally) or include an absorption (e.g. intramuscularly, subcutaneously, intracutaneously, percutaneously or intraperitoneally).
- Administration forms suitable for parenteral administration include preparations for injection and infusion in the form of solutions, suspensions, emulsions, lyophilizates or sterile powders.
- suitable examples are inhalable medicament forms (including powder inhalers, nebulizers), nasal drops, solutions or sprays, tablets, films/wafers or capsules for lingual, sublingual or buccal administration, suppositories, car or eye preparations, vaginal capsules, aqueous suspensions (lotions, shaking mixtures), lipophilic suspensions, ointments, creams, transdermal therapeutic systems (e.g. patches), milk, pastes, foams, sprinkling powders, implants or stents.
- Oral or parenteral administration is preferred, especially oral administration.
- the compounds according to the invention can be converted to the administration forms mentioned. This can be done in a manner known per se, by mixing with inert, nontoxic, pharmaceutically suitable excipients.
- excipients include carriers (for example microcrystalline cellulose, lactose, mannitol), solvents (e.g. liquid polyethylene glycols), emulsifiers and dispersing or wetting agents (for example sodium dodecylsulphate, polyoxysorbitan oleate), binders (for example polyvinylpyrrolidone), synthetic and natural polymers (for example albumin), stabilizers (e.g. antioxidants, for example ascorbic acid), dyes (e.g. inorganic pigments, for example iron oxides) and flavour and/or odour correctants.
- carriers for example microcrystalline cellulose, lactose, mannitol
- solvents e.g. liquid polyethylene glycols
- emulsifiers and dispersing or wetting agents for example sodium do
- the dosage is about 0.01 to 100 mg/kg, preferably about 0.01 to 20 mg/kg and most preferably 0.1 to 10 mg/kg of body weight.
- Method 1 MS instrument type: Waters ZQ; apparatus type HPLC: Agilent 1100 Series; UV DAD; column: Thermo Hypersil GOLD 3 ⁇ 20 mm ⁇ 4 mm; mobile phase A: 1 l of water+0.5 ml of 50% strength formic acid, mobile phase B: 1 l of acetonitrile+0.5 ml of 50% strength formic acid; gradient: 0.0 min 100% A 3.0 min 10% A 4.0 min 10% A 4.1 min 100% A (flow rate 2.5 ml/min); oven: 55° C.; flow rate: 2 ml/min; UV detection: 210 nm.
- Method 2 Instrument: Waters ACQUITY SQD UPLC System; column: Waters Acquity UPLC HSS T3 1.8 ⁇ 50 ⁇ 1 mm; mobile phase A: 1 l of water+0.25 ml of 99% strength formic acid, mobile phase B: 1 l of acetonitrile+0.25 ml of 99% strength formic acid; gradient: 0.0 min 90% A ⁇ 1.2 min 5% A ⁇ 2.0 min 5% A oven: 50° C.; flow rate: 0.40 ml/min; UV detection: 210-400 nm.
- Method 3 Instrument: Micromass Quattro Premier with Waters UPLC Acquity; column: Thermo Hypersil GOLD 1.9 ⁇ 50 mm ⁇ 1 mm; mobile phase A: 1 l of water+0.5 ml of 50% strength formic acid, mobile phase B: 1 l of acetonitrile+0.5 ml of 50% strength formic acid; gradient: 0.0 min 90% A 0.1 min 90% A 1.5 min 10% A 2.2 min 10% A; oven 50° C.; flow rate: 0.33 ml/min;
- UV detection 210 nm.
- PLM The polarized light microscopy was carried out using a Clemex PS3 polarized light microscope particle size system with a Leica DM microscope procided with 50 ⁇ , 100 ⁇ , 200 ⁇ , and 500 ⁇ lenses, a high-resolution monochrome 1600 ⁇ 1200 pixel digital camera and a motorized X-Y Marzhauser station (controlled by a Clemex ST-2000 controller).
- the samples of the crystalline material were measured on a glass slide (76 ⁇ 26 mm) in a drop of oil, the sample being covered with a cover glass (22 ⁇ 40 mm).
- the melting points were determined by dynamic differential calorimetry. The determination was carried out using a Mettler-Toledo 823e DSC instrument provided with a TSO801RO sample robot and STAR e software. About 1.5 to 3 mg of the sample were weighed out into a small aluminium pan, which was then closed with a perforated cap. The heat flow was measured in a temperature range of from 30 to 400° C. at a heating rate of 10° C./min and under an argon stream of 30 ml/min.
- thermogravimetric analysis was carried out using a Mettler-Toledo TGA/SDTA851 e TGA instrument provided with a TSO801RO sample robot and STAR e software. About 1.5 to 3 mg of the sample were weighed out into a small open aluminium pan (100 The sample weight was measured in a temperature range of from 30 to 400° C. at a heating rate of 10° C./min and under an argon stream of 30 ml/min.
- reaction mixture was filtered with suction through kieselguhr and the filter product was washed three times with ethyl acetate (517 ml each time).
- the organic phase was separated off and the aqueous phase was washed with ethyl acetate (258 ml).
- the combined organic phases were washed once with saturated aqueous sodium hydrogen carbonate solution (414 ml), dried and concentrated under reduced pressure.
- Dichloromethane (388 ml) was added to the crystals obtained in this manner, and the mixture was stirred for 20 min. The mixture was once more filtered off with suction, washed with diethyl ether and sucked dry.
- the diazonium salt thus prepared was added to a cold (0° C.) solution of 12.81 g (85.45 mmol) of sodium iodide in acetone (329 ml), and the mixture was stirred at RT for 30 min.
- the reaction mixture was poured into ice-water (1.8 l) and extracted twice with ethyl acetate (487 ml each time).
- the collected organic phases were washed with saturated aqueous sodium chloride solution (244 ml), dried, filtered and concentrated. This gave 12.1 g (86% purity, 60% of theory) of the desired compound in the form of a brown solid.
- the crude product was reacted without further purification.
- the aqueous phase was separated off and extracted two more times with ethyl acetate (200 ml each time).
- the combined organic phases were washed twice with 10% strength aqueous sodium chloride solution (100 ml each time), dried and concentrated under reduced pressure.
- the crude product was reacted without further purification.
- the mixture was then concentrated to dryness and the residue was taken up in water (100 ml) and ethyl acetate (100 ml) and adjusted to a pH of 10 using 2N aqueous sodium hydroxide solution.
- the mixture was stirred intensively at RT for about 1 h.
- the resulting suspension was filtered with suction and the filter product was washed with ethyl acetate (100 ml), with water (100 ml) and once more with ethyl acetate (100 ml).
- the residue was dried under high vacuum over phosphorus pentoxide.
- a quantity of 3.470 g (8.138 mmol) of the compound from Example 1 was suspended in 35 ml of THF, admixed at 0° C. with 358 mg (8.952 mmol) of sodium hydride (60% suspension in mineral oil) and stirred at 0° C. for 90 min, in the course of which a solution was formed.
- a quantity of 2.519 g (8.952 mmol) of 2,2,2-trifluoroethyl trichloromethanesulphonate was added and the mixture was stirred at RT for 48 h. It was then stirred with water and concentrated on a rotary evaporator.
- Example 1 A solution of 100 mg (0.235 mmol) of Example 1 in 2 ml of 1,4-dioxane was prepared in a brown 5 ml glass bottle. In succession, 2 ml of isopropanol and 235 ⁇ l (0.235 mmol) of 1M hydrochloric acid were added to this solution, and the solution was stirred at RT until the solvents had evaporated. Air-drying gave 102 mg (94% of theory) of the title compound.
- TGA 1% weight loss at 80° C.
- Example 1 A solution of 100 mg (0.235 mmol) of Example 1 in 2 ml of 1,4-dioxane was prepared in a brown 5 ml glass bottle. In succession, 2 ml of isopropanol and a solution of 938 ⁇ l (0.235 mmol) of 0.25M sulphuric acid were added to this solution, and the solution was stirred at RT until the solvents had evaporated. Air-drying gave 103 mg (83.7% of theory) of the title compound.
- Example 1 A solution of 100 mg (0.235 mmol) of Example 1 in 2 ml of 1,4-dioxane was prepared in a brown 5 ml glass bottle. In succession, 2 ml of THF and a solution of 16 ⁇ l (0.235 mmol) of 85% strength phosphoric acid in 0.3 ml of water were added to this solution, and the solution was stirred at RT until the solvents had evaporated. Air-drying gave 105 mg (85.4% of theory) of the title compound.
- Example 1 A solution of 100 mg (0.235 mmol) of Example 1 in 2 ml of 1,4-dioxane was prepared in a brown 5 ml glass bottle. In succession, 2 ml of ethanol and a solution of 22.5 mg (0.235 mmol) of methanesulphonic acid in 0.3 ml of water were added to this solution, and the solution was stirred at RT until the solvents had evaporated. Air-drying gave 103 mg (84% of theory) of the title compound.
- Example 1 A solution of 100 mg (0.235 mmol) of Example 1 in 2 ml of 1,4-dioxane was prepared in a brown 5 ml glass bottle. In succession, 2 ml of isopropanol and 44.6 mg (0.235 mmol) of ethane-1,2-disulphonic acid were added to this solution, and the solution was stirred at RT until the solvents had evaporated. Air-drying gave 111 mg (73.7% of theory) of the title compound.
- Example 1 A solution of 100 mg (0.235 mmol) of Example 1 in 2 ml of 1,4-dioxane was prepared in a brown 5 ml glass bottle. In succession, 2 ml of isopropanol and 27.2 mg (0.235 mmol) of maleic acid were added to this solution, and the solution was stirred at RT until the solvents had evaporated. Air-drying gave 108 mg (84.9% of theory) of the title compound.
- Example 1 A solution of 100 mg (0.235 mmol) of Example 1 in 2 ml of isopropanol was prepared in a brown 5 ml glass bottle. In succession, 2 ml of isopropanol and 0.235 ⁇ l (0.235 mmol) of 1M nitric acid were added to this solution, and the solution was stirred at RT until the solvents had evaporated. Air-drying gave 103 mg (89.7% of theory) of the title compound.
- Rabbits are stunned by a blow to the neck and exsanguinated.
- the aorta is removed, freed from adhering tissue and divided into rings of a width of 1.5 mm.
- the rings are placed individually under an initial tension in 5 ml organ baths with Krebs-Henseleit solution which is at 37° C., is gassed with carbogen and has the following composition (in each case mM): sodium chloride 119; potassium chloride: 4.8; calcium chloride dihydrate: 1; magnesium sulphate heptahydrate: 1.4; potassium dihydrogenphosphate: 1.2; sodium bicarbonate: 25; glucose: 10.
- the force of contraction is detected with Statham UC2 cells, amplified and digitized via A/D converters (DAS-1802 HC, Keithley Instruments, Kunststoff) and recorded in parallel on chart recorders.
- A/D converters DAS-1802 HC, Keithley Instruments, Kunststoff
- phenylephrine is added to the bath cumulatively in increasing concentration.
- the substance to be investigated is added in each further run in increasing dosage in each case, and the height of the contraction achieved is compared with the height of the contraction reached in the last preceding run.
- the concentration necessary to reduce the height of the control value by 50% is calculated from this (IC 50 value).
- the standard administration volume is 5 ⁇ l and the proportion of DMSO in the bath solution corresponds to 0.1%.
- the cellular activity of the compounds according to the invention is determined using a recombinant guanylate cyclase reporter cell line, as described in F. Wunder et al., Anal. Biochem. 339, 104-112 (2005).
- the system consists of 3 main components:
- the telemetry system makes it possible to continuously record blood pressure, heart rate and body motions of conscious animals in their usual habitat.
- the experimental animals After transmitter implantation, the experimental animals are housed singly in type 3 Makrolon cages. They have free access to standard feed and water.
- the day/night rhythm in the experimental laboratory is changed by the room lighting at 6.00 am and at 7.00 pm.
- the telemetry transmitters TA11 PA-C40 used are surgically implanted under aseptic conditions in the experimental animals at least 14 days before the first experimental use.
- the animals instrumented in this way can be employed repeatedly after the wound has healed and the implant has settled.
- the fasted animals are anaesthetized with pentobarbital (Nembutal, Sanofi: 50 mg/kg i.p.) and shaved and disinfected over a large area of their abdomens.
- pentobarbital Nembutal, Sanofi: 50 mg/kg i.p.
- the liquid-filled measuring catheter of the system is inserted into the descending aorta in the cranial direction above the bifurcation and fixed with tissue glue (VetBonDTM, 3M).
- the transmitter housing is fixed intraperitoneally to the abdominal wall muscle, and layered closure of the wound is performed.
- An antibiotic (Tardomyocel COMP, Bayer, 1 ml/kg s.c.) is administered postoperatively for prophylaxis of infection.
- the test substances are dissolved in suitable solvent mixtures, or suspended in 0.5% strength Tylose, appropriate for an administration volume of 5 ml/kg of body weight.
- a solvent-treated group of animals is employed as control.
- the telemetry measuring unit present is configured for 24 animals. Each experiment is recorded under an experiment number (Vyear month day).
- Each of the instrumented rats living in the system is assigned a separate receiving antenna (1010 Receiver, DSI).
- the implanted transmitters can be activated externally by means of an incorporated magnetic switch and are switched to transmission in the run-up to the experiment.
- the emitted signals can be detected online by a data acquisition system (DataquestTM A.R.T. for Windows, DSI) and be appropriately processed.
- the data are stored in each case in a file created for this purpose and bearing the experiment number.
- the acquisition of measured values is repeated under computer control at 5-minute intervals.
- the source data obtained as absolute value are corrected in the diagram with the currently measured barometric pressure (Ambient Pressure Reference Monitor; APR-1) and stored as individual data. Further technical details are given in the extensive documentation from the manufacturing company (DSI).
- test substances are administered at 9.00 am on the day of the experiment. Following the administration, the parameters described above are measured over 24 hours.
- the acquired individual data are sorted using the analysis software (DataquestTM A.R.T.TM Analysis).
- the blank value is assumed to be the time 2 hours before administration of the substance, so that the selected data set includes the period from 7.00 am on the day of the experiment to 9.00 am on the following day.
- the data are smoothed over a presettable time by determination of the average (15-minute average) and transferred as a text file to a storage medium.
- the measured values presorted and compressed in this way are transferred into Excel templates and tabulated.
- the data obtained are stored in a dedicated file carrying the number of the experiment. Results and test protocols are filed in paper form sorted by numbers.
- Example 2 Dosage Dosage 0.3 mg/kg 3.0 mg/kg 0.3 mg/kg Vehicle p.o. p.o. Vehicle p.o. hours mean mean mean mean hours mean mean after blood blood blood after blood blood substance pressure pressure pressure substance pressure pressure administration (mm Hg) (mm Hg) administration (mm Hg) (mm Hg) 0 153.6 151.0 149.0 0 149.0 161.3 1 164.5 148.4 129.3 1 158.2 145.7 2 146.7 136.4 111.1 2 142.2 130.5 3 145.4 130.6 106.0 3 149.2 121.5 4 149.6 129.1 107.8 4 152.3 123.1 5 149.9 132.8 109.3 5 155.8 121.6 6 151.6 125.6 106.8 6 147.3 123.8 7 147.6 131.9 110.9 7 147.3 124.4 8 147.5 131.8 109.8 8 149.3 128.7 9 150.8 138.5 114.3 9 151.0 133.7 10
- the pharmacokinetic parameters of the substance are determined in male CD-1 mice, male Wistar rats and female beagles.
- the administration volume is 10 ml/kg for mice, 5 ml/kg for rats and 0.5 ml/kg for dogs.
- Intravenous administration is via a formulation of species-specific plasma/DMSO (99/1) in the case of mice and rats and via water/PEG400/ethanol (50/40/10) in the case of dogs.
- a silicone catheter is inserted into the right Vena jugularis externa of the rats before the administration of substance.
- Substance administration is as i.v. bolus in the case of mice, as i.v. bolus or via a 15-minute infusion in the case of rats and via a 15-minute infusion in the case of dogs.
- Removal of blood is after 0.033, 0.083, 0.17, 0.5, 1, 2, 3, 4, 6, 7 and 24 hours in the case of mice and, after a 15-minute infusion, after 0.083, 0.25, 0.28 0.33, 0.42, 0.75, 1, 2, 3, 4, 6, 7 and 24 hours in the case of dogs and rats and after an i.v. bolus administration, after 0.033, 0.083, 0.17, 0.5, 1, 2, 3, 4, 6, 7 and 24 hours in the case of rats.
- oral administration of the dissolved substance via gavage is carried out based on a water/PEG400/ethanol formulation (50/40/10).
- the removal of blood from rats and dogs is after 0.083, 0.17, 0.5, 0.75, 1, 2, 3, 4, 6, 7 and 24 hours.
- the blood is removed into heparinized tubes.
- the blood plasma is then obtained by centrifugation; if required, it can be stored at ⁇ 20° C. until further processing.
- Example 1 a binary mobile phase gradient at 400 ⁇ l/min is used (A: 0.01M ammonium acetate buffer pH 6.8, B: 0.1% formic acid in acetonitrile): 0 min (90% A), 1 min (90% A), 3.5 min (15% A), 4.5 min (15% A), 4.6 min (90% A), 7 min (90% A).
- Example 2 a binary mobile phase gradient at 500 ⁇ l/min is used instead (A: 0.01M ammonium acetate buffer pH 3.0, B: 0.1% formic acid in acetonitrile): 0 min (90% A), 1.5 min (90% A), 3.5 min (10% A), 4.5 min (10% A), 5 min (90% A), 7 min (90% A).
- Example 3 a binary mobile solvent gradient at 500 ⁇ l/min is used instead (A: 0.01M ammonium acetate buffer pH 6.8, B: 0.1% formic acid in acetonitrile): 0 min (90% A), 1 min (90% A), 3 min (10% A), 4 min (10% A), 4.5 min (90% A), 6 min (90% A).
- the temperature of the Turbo V ion source is 500° C.
- Example 2 The following MS instrument parameters are used: curtain gas 20 units (Example 1), 16 units (Example 2) or 15 units (Example 3), ion spray voltage 5 kV (Example 1/2) or 4.5 units (Example 3), gas 1 35 units (Example 1/3) or 25 units (Example 2), gas 2 30 units, CAD gas 4 units (Example 1/3) or 3 units (Example 2).
- the substances are quantified by peak heights or areas using extracted ion chromatograms of specific MRM experiments.
- the plasma concentration/time plots determined are used to calculate the pharmacokinetic parameters such as AUC, C max , MRT (mean residence time), t 1/2 (half life) and CL (clearance) employing the validated pharmacokinetic calculation programs KinEx (Vers. 2.5 and 3).
- the substance quantification is carried out in plasma, it is necessary to determine the blood/plasma distribution of the substance to be able to adjust the pharamacokinetic parameters in an appropriate manner.
- a defined amount of substance is incubated in heparinized whole blood of the species in question in a rocking roller mixer for 20 min. After centrifugation at 1000 g, the plasma concentration is measured (see above) and determined by calculating the quotient of the c b /c p values.
- the substances according to the invention show a surprisingly favourable safety profile in vivo which was established by non-clinical safety studies according to OECD (OECD guidelines for testing of chemicals, No. 407) and ICH (3BS2A) guidelines.
- the compounds according to the invention can be converted to pharmaceutical formulations as follows
- the mixture of the compound according to the invention, lactose and starch is granulated with a 5% solution (w/w) of the PVP in water. After drying, the granules are mixed with the magnesium stearate for 5 minutes. This mixture is pressed with a conventional tableting press (for tablet dimensions see above).
- the guide value used for the pressing is a pressing force of 15 kN.
- a single dose of 100 mg of the compound according to the invention corresponds to 10 ml of oral suspension.
- Rhodigel is suspended in ethanol and the compound according to the invention is added to the suspension.
- the water is added while stirring.
- the mixture is stirred for approx. 6 h until swelling of the Rhodigel has ended.
- a single dose of 100 mg of the compound according to the invention corresponds to 20 g of oral solution.
- the compound according to the invention is suspended in the mixture of polyethylene glycol and polysorbate while stirring. The stirring operation is continued until dissolution of the compound according to the invention is complete.
- the compound according to the invention is dissolved in a concentration below the saturation solubility in a physiologically acceptable solvent (e.g. isotonic saline, glucose solution 5% and/or PEG 400 solution 30%).
- a physiologically acceptable solvent e.g. isotonic saline, glucose solution 5% and/or PEG 400 solution 30%.
- the solution is subjected to sterile filtration and dispensed into sterile and pyrogen-free injection vessels.
Abstract
Description
- R1 represents hydrogen or (C1-C4)-alkyl,
- where (C1-C4)-alkyl may be substituted by one or two substituents independently of one another selected from the group consisting of fluorine and trifluoromethyl,
and their N-oxides, salts, solvates, salts of the N-oxides and solvates of the N-oxides and salts.
- where (C1-C4)-alkyl may be substituted by one or two substituents independently of one another selected from the group consisting of fluorine and trifluoromethyl,
- R1 represents hydrogen or methyl,
- methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate
- methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamate
- methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}(2,2,2-trifluoroethyl)carbamate
- methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate hydrochloride
- methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate sulphate
- methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate phosphate
- methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate mesylate
- methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate ethane-1,2-disulphonate
- methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate maleate
- methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate nitrate
- [A] is reacted in an inert solvent in the presence of hexabutyltin and a suitable palladium catalyst with intermediate formation of a tin species with the compound of the formula (III)
-
- to give the compound of the formula (IV)
-
- this is then reduced in an inert solvent with a suitable reducing agent to give the compound of the formula (V)
-
- and this is then reacted in the presence of a suitable base in the presence or absence of a solvent with methyl chloroformate to give the compound of the formula (I-A)
- [B] the compound of the formula (II) is reacted in an inert solvent with copper cyanide to give the compound of the formula (VI)
-
- this is then, under acidic conditions, converted into the compound of the formula (VII)
-
- this is subsequently reacted in an inert solvent in the presence of a suitable base with the compound of the formula (VIII)
-
- to give the compound of the formula (IX)
-
- and this is then reduced in an inert solvent in the presence of a suitable reducing agent to give the compound (V), and this is subsequently reacted further according to process [A] to give compound (I-A),
or
- and this is then reduced in an inert solvent in the presence of a suitable reducing agent to give the compound (V), and this is subsequently reacted further according to process [A] to give compound (I-A),
- [C] the compound of the formula (I-A) is reacted in an inert solvent in the presence of a suitable base with a compound of the formula (X)
R1A—X1 (X),- R1A represents (C1-C4)-alkyl,
- where (C1-C4)-alkyl may be substituted by one or two substituents independently of one another selected from the group consisting of fluorine and trifluoromethyl,
- and
- X1 represents a leaving group such as, for example, halogen, in particular bromine or iodine, trichloromethanesulphonate, mesylate or tosylate
- to give a compound of the formula (I-B)
- R1A represents (C1-C4)-alkyl,
-
- in which R1A has the meaning given above,
and the resulting compounds of the formulae (I-A) and (I-B) are, where appropriate, converted with the appropriate (i) solvents and/or (ii) acids or bases into their solvates, salts and/or solvates of the salts.
- in which R1A has the meaning given above,
then reacting this compound in an inert solvent in the presence of a suitable Lewis acid initially with isopentyl nitrite to give the corresponding diazonium salt and then converting this salt directly with sodium iodide into the compound of the formula (XII)
and then reacting this compound in an inert solvent in the presence of a suitable base with the compound of the formula (XIII)
-
- organic nitrates and NO donors, for example sodium nitroprusside, nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, molsidomine or SIN-1, and inhaled NO;
- compounds which inhibit the breakdown of cyclic guanosine monophosphate (cGMP), such as, for example, inhibitors of phosphodiesterases (PDE) 1, 2 and/or 5, in particular PDE 5 inhibitors such as sildenafil, vardenafil and tadalafil;
- agents having an antithrombotic effect, for example and with preference from the group of platelet aggregation inhibitors, of anticoagulants or of profibrinolytic substances;
- active compounds which lower blood pressure, for example and preferably from the group of calcium antagonists, angiotensin AII antagonists, ACE inhibitors, endothelin antagonists, renin inhibitors, alpha-receptor blockers, beta-receptor blockers, mineralocorticoid receptor antagonists, and of diuretics; and/or
- active compounds which alter lipid metabolism, for example and with preference from the group of thyroid receptor agonists, cholesterol synthesis inhibitors such as, by way of example and preferably, HMG-CoA reductase inhibitors or squalene synthesis inhibitors, of ACAT inhibitors, CETP inhibitors, MTP inhibitors, PPAR-alpha, PPAR-gamma and/or PPAR-delta agonists, cholesterol absorption inhibitors, lipase inhibitors, polymeric bile acid adsorbents, bile acid reabsorption inhibitors and lipoprotein(a) antagonists;
- aq. aqueous solution
- calc. calculated
- br s broad singlet (in NMR)
- DCI direct chemical ionization (in MS)
- dec. decomposition point
- DMF dimethylformamide
- DMSO dimethyl sulphoxide
- DSC dynamic differential calorimetry
- eq. equivalent(s)
- ESI electrospray ionization (in MS)
- Et ethyl
- fnd. found
- h hour(s)
- HPLC high-pressure high-performance liquid chromatography
- HRMS high-resolution mass spectrometry
- conc. concentrated
- LC-MS liquid chromatography-coupled mass spectrometry
- LiHMDS lithium hexamethyldisilazide
- Me methyl
- min minute(s)
- MS mass spectrometry
- NMR nuclear magnetic resonance spectrometry
- Pd2dba3 tris(dibenzylideneacetone)dipalladium
- Ph phenyl
- PLM polarized light microscope
- RT room temperature
- Rt retention time (in HPLC)
- TGA thermogravimetric analysis
- THF tetrahydrofuran
- UV ultraviolet spectrometry
- v/v volume to volume ratio (of a solution)
LC/MS Methods:
TABLE 1 | ||
Example No. | IC50 [nM] | |
1 | 958 | |
2 | 251 | |
3 | 515 | |
B-2. Effect on a Recombinant Guanylate Cyclase Reporter Cell Line
TABLE 2 | ||
Example No. | MEC [μM] | |
1 | 0.3 | |
2 | 0.1 | |
3 | 0.03 | |
B-3. Radiotelemetric Measurement of Blood Pressure on Conscious Spontaneously Hypertensive Rats
-
- implantable transmitters (Physiotel® telemetry transmitter)
- receivers (Physiotel® receiver) which are linked via a multiplexer (DSI Data Exchange Matrix) to a
- data acquisition computer.
-
- systolic blood pressure (SBP)
- diastolic blood pressure (DBP)
- mean arterial pressure (MAP)
- heart rate (HR)
- activity (ACT).
TABLE 3 | |
Example 1: | Example 2: |
Dosage | Dosage | Dosage | ||||
0.3 mg/kg | 3.0 mg/kg | 0.3 mg/kg | ||||
Vehicle | p.o. | p.o. | Vehicle | p.o. | ||
hours | mean | mean | mean | hours | mean | mean |
after | blood | blood | blood | after | blood | blood |
substance | pressure | pressure | pressure | substance | pressure | pressure |
administration | (mm Hg) | (mm Hg) | (mm Hg) | administration | (mm Hg) | (mm Hg) |
0 | 153.6 | 151.0 | 149.0 | 0 | 149.0 | 161.3 |
1 | 164.5 | 148.4 | 129.3 | 1 | 158.2 | 145.7 |
2 | 146.7 | 136.4 | 111.1 | 2 | 142.2 | 130.5 |
3 | 145.4 | 130.6 | 106.0 | 3 | 149.2 | 121.5 |
4 | 149.6 | 129.1 | 107.8 | 4 | 152.3 | 123.1 |
5 | 149.9 | 132.8 | 109.3 | 5 | 155.8 | 121.6 |
6 | 151.6 | 125.6 | 106.8 | 6 | 147.3 | 123.8 |
7 | 147.6 | 131.9 | 110.9 | 7 | 147.3 | 124.4 |
8 | 147.5 | 131.8 | 109.8 | 8 | 149.3 | 128.7 |
9 | 150.8 | 138.5 | 114.3 | 9 | 151.0 | 133.7 |
10 | 149.8 | 138.3 | 114.5 | 10 | 152.5 | 139.2 |
11 | 154.0 | 138.9 | 115.6 | 11 | 150.3 | 137.9 |
12 | 145.3 | 137.7 | 118.8 | 12 | 146.2 | 143.0 |
13 | 141.1 | 142.9 | 120.4 | 13 | 143.2 | 146.0 |
14 | 147.8 | 144.5 | 122.8 | 14 | 146.4 | 149.2 |
15 | 151.0 | 143.8 | 125.8 | 15 | 150.5 | 152.3 |
16 | 151.3 | 146.3 | 131.5 | 16 | 145.3 | 155.5 |
17 | 148.8 | 141.8 | 124.7 | 17 | 143.9 | 156.3 |
18 | 149.2 | 138.4 | 129.6 | 18 | 150.3 | 157.3 |
19 | 151.2 | 149.2 | 135.6 | 19 | 147.7 | 156.9 |
20 | 152.6 | 145.1 | 135.2 | 20 | 153.4 | 156.3 |
21 | 146.3 | 142.1 | 129.3 | 21 | 148.6 | 149.3 |
22 | 146.3 | 141.8 | 128.3 | 22 | 153.3 | 147.1 |
23 | 150.3 | 143.6 | 130.2 | 23 | 151.1 | 153.1 |
24 | 147.4 | 135.1 | 130.8 | 24 | 154.1 | 152.3 |
- Klaus Witte, Kai Hu, Johanna Swiatek, Claudia Müssig, Georg Ertl and Björun Lemmer: Experimental heart failure in rats: effects on cardiovascular circadian rhythms and on myocardial β-adrenergic signaling. Cardiovasc Res 47 (2): 203-405, 2000; Kozo Okamoto: Spontaneous hypertension in rats. Int Rev Exp Pathol 7: 227-270, 1969; Maarten van den Buuse: Circadian Rhythms of Blood Pressure, Heart Rate, and Locomotor Activity in Spontaneously Hypertensive Rats as Measured With Radio-Telemetry. Physiology & Behavior 55(4): 783-787, 1994
B-4. Determination of Pharmacokinetic Parameters Following Intravenous and Peroral Administration:
Example |
1.* | 2.** | 3.** | ||
AUCnorm [kg · h/l] | 4.36 | 1.79 | 1.36 | |
CLblood [lh/kg] | 0.29 | 0.53 | 1.02 | |
MRT [h] | 4.1 | 2.3 | 2.3 | |
t1/2 [h] | 3.4 | 1.7 | 1.9 | |
*15-minute infusion | ||||
**i.v. bolus administration |
B-5. Safety Profile
Claims (66)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/919,385 US11439642B2 (en) | 2010-05-26 | 2020-07-02 | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
US17/820,667 US20220409618A1 (en) | 2010-05-26 | 2022-08-18 | Substituted 5-fluoro-1h-pyrazolopyridines and their use |
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102010021637A DE102010021637A1 (en) | 2010-05-26 | 2010-05-26 | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
DE102010021637.2 | 2010-05-26 | ||
US13/111,856 US8420656B2 (en) | 2010-05-26 | 2011-05-19 | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
US13/851,373 US8921377B2 (en) | 2010-05-26 | 2013-03-27 | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
US14/552,122 US9266885B2 (en) | 2010-05-26 | 2014-11-24 | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
US14/996,678 US20160129004A1 (en) | 2010-05-26 | 2016-01-15 | Substituted 5-fluoro-1h-pyrazolopyridines and their use |
US15/348,545 US9993476B2 (en) | 2010-05-26 | 2016-11-10 | Substituted 5-flouro-1H-pyrazolopyridines and their use |
US15/981,598 US10736896B2 (en) | 2010-05-26 | 2018-05-16 | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
US16/919,385 US11439642B2 (en) | 2010-05-26 | 2020-07-02 | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/981,598 Division US10736896B2 (en) | 2010-05-26 | 2018-05-16 | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/820,667 Continuation US20220409618A1 (en) | 2010-05-26 | 2022-08-18 | Substituted 5-fluoro-1h-pyrazolopyridines and their use |
Publications (2)
Publication Number | Publication Date |
---|---|
US20200397785A1 US20200397785A1 (en) | 2020-12-24 |
US11439642B2 true US11439642B2 (en) | 2022-09-13 |
Family
ID=44119218
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/111,856 Active US8420656B2 (en) | 2010-05-26 | 2011-05-19 | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
US13/851,373 Active US8921377B2 (en) | 2010-05-26 | 2013-03-27 | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
US14/552,122 Active US9266885B2 (en) | 2010-05-26 | 2014-11-24 | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
US14/996,678 Abandoned US20160129004A1 (en) | 2010-05-26 | 2016-01-15 | Substituted 5-fluoro-1h-pyrazolopyridines and their use |
US15/348,545 Active US9993476B2 (en) | 2010-05-26 | 2016-11-10 | Substituted 5-flouro-1H-pyrazolopyridines and their use |
US15/981,598 Active US10736896B2 (en) | 2010-05-26 | 2018-05-16 | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
US16/919,385 Active US11439642B2 (en) | 2010-05-26 | 2020-07-02 | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
US17/820,667 Pending US20220409618A1 (en) | 2010-05-26 | 2022-08-18 | Substituted 5-fluoro-1h-pyrazolopyridines and their use |
Family Applications Before (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/111,856 Active US8420656B2 (en) | 2010-05-26 | 2011-05-19 | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
US13/851,373 Active US8921377B2 (en) | 2010-05-26 | 2013-03-27 | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
US14/552,122 Active US9266885B2 (en) | 2010-05-26 | 2014-11-24 | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
US14/996,678 Abandoned US20160129004A1 (en) | 2010-05-26 | 2016-01-15 | Substituted 5-fluoro-1h-pyrazolopyridines and their use |
US15/348,545 Active US9993476B2 (en) | 2010-05-26 | 2016-11-10 | Substituted 5-flouro-1H-pyrazolopyridines and their use |
US15/981,598 Active US10736896B2 (en) | 2010-05-26 | 2018-05-16 | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/820,667 Pending US20220409618A1 (en) | 2010-05-26 | 2022-08-18 | Substituted 5-fluoro-1h-pyrazolopyridines and their use |
Country Status (45)
Families Citing this family (143)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102008063992A1 (en) * | 2008-12-19 | 2010-09-02 | Lerner, Zinoviy, Dipl.-Ing. | New aliphatic substituted pyrazolopyridines and their use |
DK2733142T3 (en) | 2009-11-27 | 2018-11-19 | Adverio Pharma Gmbh | Process for the preparation of methyl {4,6-diamino-2- [1- (2-fluorobenzyl) -1H-pyrazolo [3,4-b] pyridin-3-yl] pyrimidin-5-yl} methylcarbamate for use as pharmaceutical active ingredient |
EP2549875B1 (en) | 2010-03-25 | 2015-05-13 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
DE102010021637A1 (en) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
EA023254B1 (en) | 2010-05-27 | 2016-05-31 | Мерк Шарп Энд Домэ Корп. | Soluble guanylate cyclase activators |
AU2011275825A1 (en) | 2010-07-09 | 2013-02-07 | Bayer Intellectual Property Gmbh | Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases |
WO2012058132A1 (en) | 2010-10-28 | 2012-05-03 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
DE102010043379A1 (en) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituted 6-fluoro-1H-pyrazolo [4,3-b] pyridines and their use |
DE102010043380A1 (en) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Benzyl-substituted carbamates and their use |
DE102011007272A1 (en) | 2011-04-13 | 2012-10-18 | Bayer Pharma Aktiengesellschaft | Branched 3-phenylpropionic acid derivatives and their use |
CA2833698A1 (en) | 2011-04-21 | 2012-10-26 | Bayer Intellectual Property Gmbh | Fluoroalkyl-substituted pyrazolopyridines and use thereof |
EP2594270A3 (en) * | 2011-11-18 | 2013-07-31 | BIP Patents | The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) |
KR101993022B1 (en) * | 2011-11-25 | 2019-06-25 | 아드베리오 파마 게엠베하 | Method for producing substituted 5-fluoro-1h-pyrazolopyridines |
CN102491974B (en) | 2011-12-12 | 2013-08-07 | 南京药石药物研发有限公司 | Method for synthesizing 1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-formamidine hydrochloride |
DE102012200360A1 (en) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituted triazines and their use |
DE102012200349A1 (en) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituted fused pyrimidines and triazines and their use |
DE102012200352A1 (en) * | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituted, fused imidazoles and pyrazoles and their use |
ES2644781T3 (en) | 2012-03-06 | 2017-11-30 | Bayer Intellectual Property Gmbh | Azabicycles substituted and their use |
WO2013144191A1 (en) | 2012-03-29 | 2013-10-03 | Bayer Intellectual Property Gmbh | Substituted 2-amino-3-cyanopyridines as inhibitors of sodium-calcium exchange and use thereof for cardiovascular diseases |
US9387203B2 (en) | 2012-07-20 | 2016-07-12 | Bayer Pharma Aktiengesellschaft | Substituted aminoindane- and aminotetralinecarboxylic acids and the use thereof |
BR112015001211B1 (en) | 2012-07-20 | 2020-12-15 | Bayer Pharma Aktiengesellschaft | 5-AMINOTETRA-HYDROQUINOLINE-2-CARBOXYLIC ACIDS, PROCESSES FOR ITS PREPARATION, ITS USES IN THE TREATMENT AND / OR PREVENTION OF DISEASES AND ITS MEDICINES |
CN104822680B (en) | 2012-11-30 | 2016-10-12 | 安斯泰来制药株式会社 | Imidazopyridine |
EP3760629A1 (en) | 2013-02-21 | 2021-01-06 | Adverio Pharma GmbH | Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate |
JP2016510010A (en) | 2013-03-01 | 2016-04-04 | バイエル・ファルマ・アクティエンゲゼルシャフト | Trifluoromethyl-substituted ring-fused pyrimidines and uses thereof |
EP3010907A1 (en) | 2013-06-21 | 2016-04-27 | Bayer Pharma Aktiengesellschaft | Diaminoheteroaryl substituted pyrazoles |
PE20160201A1 (en) | 2013-07-10 | 2016-05-06 | Bayer Pharma AG | BENCIL-1H-PYRAZOLE [3,4-B] PYRIDINES AND THEIR USE |
US10265314B2 (en) | 2013-07-25 | 2019-04-23 | Bayer Pharma Aktiengesellschaft | SGC stimulators in combination with additional treatment for the therapy of cystic fibrosis |
EP3046912A1 (en) | 2013-09-16 | 2016-07-27 | Bayer Pharma Aktiengesellschaft | Disubstituted trifluormethyl pyrimidinones and use thereof as ccr2 antagonists |
CN105793267B (en) | 2013-10-07 | 2018-02-06 | 拜耳制药股份公司 | Ring-type thieno uracil benzamide type and application thereof |
US9783552B2 (en) | 2013-12-11 | 2017-10-10 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
EP3079701B1 (en) | 2013-12-11 | 2021-08-11 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
EP3094327A1 (en) | 2014-01-13 | 2016-11-23 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS |
CN106458938A (en) | 2014-04-03 | 2017-02-22 | 拜耳制药股份公司 | Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and use thereof |
EP3126358A1 (en) | 2014-04-03 | 2017-02-08 | Bayer Pharma Aktiengesellschaft | 2,5-disubstituted cyclopentane carboxylic acids for the treatment of respiratoy tract diseases |
WO2015150363A1 (en) | 2014-04-03 | 2015-10-08 | Bayer Pharma Aktiengesellschaft | 2,5-disubstituted cyclopentane carboxylic acids and use thereof |
WO2015187470A1 (en) | 2014-06-04 | 2015-12-10 | Merck Sharp & Dohme Corp. | Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators |
CN107074773A (en) | 2014-09-09 | 2017-08-18 | 拜耳制药股份公司 | Substituted N, the formamide of 2 biaryl quinolin 4 and application thereof |
WO2016046157A1 (en) | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives |
KR20170081178A (en) | 2014-11-03 | 2017-07-11 | 바이엘 파마 악티엔게젤샤프트 | Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof |
TW201625635A (en) | 2014-11-21 | 2016-07-16 | 默沙東藥廠 | Triazolo-pyrazinyl derivatives useful as soluble guanylate cyclase activators |
WO2016113205A1 (en) | 2015-01-13 | 2016-07-21 | Bayer Pharma Aktiengesellschaft | Substituted pentafluoroethyl pyrimidinones and use thereof |
UY36586A (en) | 2015-03-26 | 2016-10-31 | Bayer Pharma AG | HETEROCICLILMETILTIENOURACILOS AND USE OF THE SAME |
TN2017000465A1 (en) | 2015-05-06 | 2019-04-12 | Bayer Pharma AG | The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc) |
EP3303342B1 (en) | 2015-05-27 | 2021-03-17 | Merck Sharp & Dohme Corp. | Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators |
EP3310782B1 (en) | 2015-05-28 | 2021-12-01 | Merck Sharp & Dohme Corp. | Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators |
JP6849618B2 (en) | 2015-07-23 | 2021-03-24 | バイエル・ファルマ・アクティエンゲゼルシャフト | Soluble guanylate cyclase (sGC) stimulants and / or activators in combination with neutral endopeptidase inhibitors (NEP inhibitors) and / or angiotensin II antagonists and their use |
WO2017097671A1 (en) | 2015-12-10 | 2017-06-15 | Bayer Pharma Aktiengesellschaft | Substituted perhydropyrrolo[3,4-c]pyrrole derivatives and the use of same |
MX2018007040A (en) | 2015-12-10 | 2018-08-15 | Bayer Pharma AG | 2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders. |
KR20180094965A (en) | 2015-12-14 | 2018-08-24 | 아이언우드 파마슈티컬스, 인코포레이티드 | Use of sGC Stimulants for the Treatment of Gastric Sphincter Dysfunction |
CN105461715B (en) * | 2015-12-15 | 2017-03-29 | 郑州大明药物科技有限公司 | A kind of synthetic method of the western croak intermediate of Leo |
WO2017107052A1 (en) | 2015-12-22 | 2017-06-29 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase stimulators |
WO2017121692A1 (en) | 2016-01-15 | 2017-07-20 | Bayer Pharma Aktiengesellschaft | Substituted sulfamides and use of same |
WO2017153234A1 (en) | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | Substituted n-cyclo-2-aryl-quinoline-4-carboxamides and use thereof |
WO2017153235A1 (en) | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | Substituted n-cyclo-3-aryl-1-naphthamides and use thereof |
WO2017153231A1 (en) | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | Substituted n-cyclo-2-aryl-isoquinolinone-4-carboxamides and use thereof |
US10525041B2 (en) | 2016-05-03 | 2020-01-07 | Bayer Pharma Aktiengesellschaft | Fluoroalkyl-substituted aryltriazole derivatives and uses thereof |
US9988367B2 (en) | 2016-05-03 | 2018-06-05 | Bayer Pharma Aktiengesellschaft | Amide-substituted pyridinyltriazole derivatives and uses thereof |
US10800746B2 (en) | 2016-05-03 | 2020-10-13 | Bayer Pharma Aktiengesellschaft | Oxoalkyl-substituted phenyltriazole derivatives and uses thereof |
US20190119251A1 (en) | 2016-05-03 | 2019-04-25 | Bayer Pharma Aktiengesellschaft | Amide-substituted aryltriazole derivatives and uses thereof |
WO2017191114A1 (en) | 2016-05-03 | 2017-11-09 | Bayer Aktiengesellschaft | Hydroxyalkyl-substituted heteroaryltriazole derivatives and uses thereof |
WO2017191117A1 (en) | 2016-05-03 | 2017-11-09 | Bayer Pharma Aktiengesellschaft | V1a receptor antagonists for use in the treatment of renal diseases |
TW201806943A (en) | 2016-05-03 | 2018-03-01 | 拜耳製藥股份有限公司 | Amide-substituted phenyltriazole derivatives and uses thereof |
JOP20170113B1 (en) | 2016-05-09 | 2023-03-28 | Bayer Pharma AG | Substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridin-3(2H)-ones and 2,5,6,7-tetrahydro-3H-pyrrolo[2,1-c][1,2,4]triazol-3-ones and use thereof |
WO2017197555A1 (en) | 2016-05-16 | 2017-11-23 | Merck Sharp & Dohme Corp. | Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators |
US10925876B2 (en) | 2016-05-18 | 2021-02-23 | Merck Sharp & Dohme Corp. | Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders |
CN109689654A (en) | 2016-07-11 | 2019-04-26 | 拜耳医药股份有限公司 | 1- pyridyl group-naphthyridines -3- benzamide type and application thereof that 7- replaces |
JOP20190005A1 (en) | 2016-07-20 | 2019-01-20 | Bayer Ag | Substituted diazahetero-bicyclic compounds and their use |
WO2018041771A1 (en) | 2016-09-02 | 2018-03-08 | Bayer Pharma Aktiengesellschaft | (1-methylcyclopropyl)methyl-substituted thienouraciles and use thereof |
JOP20190045A1 (en) | 2016-09-14 | 2019-03-14 | Bayer Ag | 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof |
EP3296298A1 (en) | 2016-09-14 | 2018-03-21 | Bayer Pharma Aktiengesellschaft | 7-substituted 1-aryl-naphthyridin-3-carboxamides and their use |
RU2019111357A (en) | 2016-09-23 | 2020-10-23 | Байер Акциенгезельшафт | N3-CYCLICALLY SUBSTITUTED THYENOURACILS AND THEIR APPLICATION |
CA3039734A1 (en) | 2016-10-11 | 2018-04-19 | Bayer Pharma Aktiengesellschaft | Combination containing sgc stimulators and mineralocorticoid receptor antagonists |
US11331308B2 (en) | 2016-10-11 | 2022-05-17 | Bayer Pharma Aktiengesellschaft | Combination containing sGC activators and mineralocorticoid receptor antagonists |
JOP20190080A1 (en) | 2016-10-14 | 2019-04-11 | Bayer Pharma AG | Substituted 6-(1h-pyrazol-1-yl)pyrimidin-4-amine derivatives and uses thereof |
US10927098B2 (en) | 2016-10-20 | 2021-02-23 | Bayer Pharma Aktiengesellschaft | Hydroxyalkyl-substituted triazole derivatives and uses thereof |
US20190381039A1 (en) | 2016-12-13 | 2019-12-19 | Cyclerion Therapeutics, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF ESOPHAGEAL MOTILITY DISORDERS |
JOP20190148A1 (en) | 2016-12-21 | 2019-06-18 | Bayer Pharma AG | Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy |
EP3338803A1 (en) | 2016-12-21 | 2018-06-27 | Bayer Pharma Aktiengesellschaft | Pharmaceutical dosage forms containing inhibitors for task-1 and task-3 channels and their use in therapy of respiratory disorders |
EP3338764A1 (en) | 2016-12-21 | 2018-06-27 | Bayer Pharma Aktiengesellschaft | Pharmaceutical dosage forms containing inhibitors for task-1 and task-3 channels and their use in therapy of respiratory disorders |
JOP20190141A1 (en) | 2016-12-21 | 2019-06-12 | Bayer Pharma AG | Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy |
WO2018153899A1 (en) * | 2017-02-22 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Selective partial adenosine a1 receptor agonists in combination with soluble guanylyl cyclase (sgc) stimulators and/or activators |
KR20190138824A (en) | 2017-04-10 | 2019-12-16 | 바이엘 악티엔게젤샤프트 | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and uses thereof |
TWI770157B (en) | 2017-04-10 | 2022-07-11 | 德商拜耳廠股份有限公司 | Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof |
CN108690016B (en) * | 2017-04-11 | 2022-08-12 | 广东东阳光药业有限公司 | Pyrazolopyridines and uses thereof |
WO2018188590A1 (en) | 2017-04-11 | 2018-10-18 | Sunshine Lake Pharma Co., Ltd. | Fluorine-substituted indazole compounds and uses thereof |
JOP20190284A1 (en) | 2017-06-14 | 2019-12-11 | Bayer Pharma AG | Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders |
WO2018227427A1 (en) | 2017-06-14 | 2018-12-20 | Bayer Aktiengesellschaft | Substituted bridged diazepane derivatives and use thereof |
WO2019081291A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | Prodrugs of substituted triazole derivatives and uses thereof |
US11149023B2 (en) | 2017-10-24 | 2021-10-19 | Bayer Pharma Aktiengesellschaft | Substituted triazole derivatives and uses thereof |
CU20200041A7 (en) * | 2017-10-24 | 2021-03-11 | Bayer Ag | SUBSTITUTE IMIDAZOPYRIDINE AMIDES |
US11230540B2 (en) | 2017-10-24 | 2022-01-25 | Bayer Pharma Aktiengesellschaft | Substituted triazole derivatives and uses thereof |
EP3700897A1 (en) | 2017-10-24 | 2020-09-02 | Bayer Pharma Aktiengesellschaft | Substituted triazole derivatives and uses thereof |
LT3700913T (en) | 2017-10-24 | 2022-01-25 | Bayer Aktiengesellschaft | Prodrugs of substituted triazole derivatives and uses thereof |
CA3079770A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Pharma Aktiengesellschaft | Amine substituted triazole derivatives and uses thereof |
EP3700900A1 (en) | 2017-10-24 | 2020-09-02 | Bayer Aktiengesellschaft | Substituted triazole derivatives and uses thereof |
EP3707141B1 (en) | 2017-11-07 | 2021-12-22 | Bayer Aktiengesellschaft | Substituted 2,4-dihydro-3h-1,2,4-triazol-3-ones and use of same |
CA3083986A1 (en) | 2017-12-01 | 2019-06-06 | Bayer Pharma Aktiengesellschaft | Method for producing (3s)-3-(4-chlor-3-{[(2s,3r)-2-(4-chlorphenyl)-4,4,4-trifluor-3-methylbutanoyl]amino}phenyl)-3-cyclo-propylpropanoic acid and the crystalline form thereof for use as a pharmaceutical ingredient |
CN111712247B (en) * | 2017-12-19 | 2024-02-09 | 塞科里昂医疗股份有限公司 | sGC stimulators |
EP3553081A1 (en) | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | Atrial natriuretic peptide engrafted antibodies |
EP3553079A1 (en) | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | C-type natriuretic peptide engrafted antibodies |
EP3553082A1 (en) | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | Brain natriuretic peptide engrafted antibodies |
US20210052528A1 (en) * | 2018-04-30 | 2021-02-25 | Bayer Aktiengesellschaft | The use of sgc activators and sgc stimulators for the treatment of cognitive impairment |
EP3566704A1 (en) | 2018-05-11 | 2019-11-13 | Bayer Aktiengesellschaft | The use of non-steroidal mineralocorticoid receptor antagonists alone or in combination for the treatment of muscular or neuromuscular diseases |
AU2019269047A1 (en) | 2018-05-15 | 2020-11-26 | Bayer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization |
EP3793559A1 (en) | 2018-05-17 | 2021-03-24 | Bayer Aktiengesellschaft | Substituted dihydropyrazolo pyrazine carboxamide derivatives |
US11508483B2 (en) | 2018-05-30 | 2022-11-22 | Adverio Pharma Gmbh | Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group |
WO2020014504A1 (en) | 2018-07-11 | 2020-01-16 | Cyclerion Therapeutics, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONRIAL DISORDERS |
EP3826619A1 (en) | 2018-07-24 | 2021-06-02 | Bayer Aktiengesellschaft | Pharmaceutical dosage form which can be administered orally and has modified release |
SG11202100369WA (en) | 2018-07-24 | 2021-02-25 | Bayer Ag | Pharmaceutical dosage form which can be administered orally and has modified release |
US10905667B2 (en) | 2018-07-24 | 2021-02-02 | Bayer Pharma Aktiengesellschaft | Orally administrable modified-release pharmaceutical dosage form |
EP3886806A1 (en) | 2018-11-27 | 2021-10-06 | Bayer Aktiengesellschaft | Process for producing pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy |
CA3123360A1 (en) | 2018-12-17 | 2020-06-25 | Adverio Pharma Gmbh | Methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate active compound product having improved properties, production and formulation thereof |
WO2020164008A1 (en) | 2019-02-13 | 2020-08-20 | Bayer Aktiengesellschaft | Process for the preparation of porous microparticles |
WO2020216669A1 (en) | 2019-04-23 | 2020-10-29 | Bayer Aktiengesellschaft | Phenyl-substituted imidazopyridine amides and use thereof |
AU2020268578A1 (en) | 2019-05-07 | 2022-02-03 | Bayer Aktiengesellschaft | MASP inhibitory compounds and uses thereof |
WO2020245342A1 (en) | 2019-06-07 | 2020-12-10 | Bayer Aktiengesellschaft | The use of sgc activators for the treatment of ophthalmologic diseases |
CA3160035A1 (en) | 2019-11-06 | 2021-05-14 | Bayer Aktiengesellschaft | Inhibitors of adrenoreceptor adrac2 |
WO2021094209A1 (en) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Substituted pyrrolo triazine carboxamide derivatives as prostaglandin ep3 receptor antagonists |
WO2021094210A1 (en) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Substituted pyrazine carboxamide derivatives as prostaglandin ep3 receptor antagonists |
WO2021094208A1 (en) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Substituted imidazo pyrimidine ep3 antagonists |
EP3822265A1 (en) | 2019-11-15 | 2021-05-19 | Bayer AG | Substituted hydantoinamides as adamts7 antagonists |
EP3822268A1 (en) | 2019-11-15 | 2021-05-19 | Bayer Aktiengesellschaft | Substituted hydantoinamides as adamts7 antagonists |
WO2021156223A1 (en) | 2020-02-03 | 2021-08-12 | Adverio Pharma Gmbh | Nanoformulations of methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate |
EP4106741A1 (en) | 2020-02-21 | 2022-12-28 | Universiteit Maastricht | Use of a soluble guanylate cyclase (sgc) stimulator or of a combination of a sgc stimulator and an sgc activator for conditions wherein the heme group of sgc is oxidized or wherein sgc is deficient in heme |
EP4110396A1 (en) | 2020-02-26 | 2023-01-04 | Universiteit Maastricht | Therapeutic combination for the treatment of brain ischemia and said therapeutic combination for use in the treatment of brain ischemia |
WO2021195403A1 (en) | 2020-03-26 | 2021-09-30 | Cyclerion Therapeutics, Inc. | Deuterated sgc stimulators |
EP3925953A1 (en) | 2020-06-16 | 2021-12-22 | Adverio Pharma GmbH | Process for preparing methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate |
EP4011904A1 (en) | 2020-12-14 | 2022-06-15 | Bayer Aktiengesellschaft | Masp inhibitory compounds and uses thereof |
US20240010684A1 (en) | 2020-11-04 | 2024-01-11 | Bayer Aktiengesellschaft | Masp inhibitory compounds and uses thereof |
WO2022112213A1 (en) | 2020-11-30 | 2022-06-02 | Bayer Aktiengesellschaft | Crystalline forms of 3-[[3-(4-chlorophenyl)-5-oxo-4-((2s)-3,3,3-trifluoro- 2-hydroxypropyl)-4,5-dihydro-1h-1,2,4-triazol-1-yl]methyl]-1-[3- (trifluoromethyl)pyridin-2-yl]-1h-1,2,4-triazole-5-carboxamide |
WO2022122914A1 (en) | 2020-12-10 | 2022-06-16 | Bayer Aktiengesellschaft | Substituted pyrazolo piperidine carboxylic acids |
EP4011873A1 (en) | 2020-12-10 | 2022-06-15 | Bayer Aktiengesellschaft | Substituted pyrazolo piperidine carboxylic acids |
EP4011874A1 (en) | 2020-12-10 | 2022-06-15 | Bayer Aktiengesellschaft | Substituted pyrazolo piperidine carboxylic acids |
CA3204595A1 (en) | 2020-12-10 | 2022-06-16 | Bayer Aktiengesellschaft | Substituted pyrazolyl piperidine carboxylic acids |
KR20230118143A (en) | 2020-12-10 | 2023-08-10 | 바이엘 악티엔게젤샤프트 | Use of sGC activators for the treatment of ophthalmic diseases |
TW202309038A (en) | 2021-04-20 | 2023-03-01 | 美商賽克瑞恩醫療公司 | Sgc stimulators |
TW202308634A (en) | 2021-04-20 | 2023-03-01 | 美商賽克瑞恩醫療公司 | Treatment of cns diseases with sgc stimulators |
WO2023034364A1 (en) | 2021-08-31 | 2023-03-09 | Teva Pharmaceuticals International Gmbh | Solid state forms of vericiguat and process for preparation thereof |
WO2023126437A1 (en) | 2021-12-29 | 2023-07-06 | Bayer Aktiengesellschaft | Treatment of cardiopulmonary disorders |
WO2023126436A1 (en) | 2021-12-29 | 2023-07-06 | Bayer Aktiengesellschaft | Process for preparing (5s)-{[2-(4-carboxyphenyl)ethyl] |2-(2-{|3-chloro-4'-(trifluoromethyl)biphenyl-4- yl]methoxy}phenyl)ethyl]aminol-5,6,7,8-tetrahydroquinoline-2-carboxylic acid and its crystalline forms for use as pharmaceutically active compound |
WO2023126438A1 (en) | 2021-12-29 | 2023-07-06 | Bayer Aktiengesellschaft | Pharmaceutical dry powder inhalation formulation |
ES2956054A1 (en) * | 2022-05-03 | 2023-12-12 | Moehs Iberica Sl | 2-(5-FLUORO-1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-b]PYRIDIN-3-IL)-5-NITROSOPYRIMIDIN-4,6-DIAMINE OR A SALT THEREOF, PROCEDURE FOR ITS PREPARATION AND ITS USE IN THE SYNTHESIS OF VERICIGUAT (Machine-translation by Google Translate, not legally binding) |
WO2023237577A1 (en) | 2022-06-09 | 2023-12-14 | Bayer Aktiengesellschaft | Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women |
Citations (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0463756A1 (en) | 1990-06-20 | 1992-01-02 | Pfizer Limited | Pyrazolopyrimidinone antianginal agents |
EP0463754A1 (en) | 1990-06-25 | 1992-01-02 | Rohm And Haas Company | Stabilization of glutarimide polymers |
CA2127624A1 (en) | 1993-07-13 | 1995-01-14 | Barry D. G. Haylor | Herbicides |
US5393761A (en) | 1990-07-30 | 1995-02-28 | H. Lundbeck A/S | 3-arylindole compounds |
US6008243A (en) | 1996-10-24 | 1999-12-28 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use |
WO2000006567A1 (en) | 1998-07-29 | 2000-02-10 | Bayer Aktiengesellschaft | 3-(4-amino-5-ethylpyrimidine-2-yl)-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridine |
WO2000021954A1 (en) | 1998-10-09 | 2000-04-20 | Bayer Aktiengesellschaft | Novel heterocyclyl-methyl-substituted pyrazoles |
US6090818A (en) | 1996-12-13 | 2000-07-18 | Sanofi-Synthelabo | Indolin-2-one derivatives, method for preparing them and pharmaceutical compositions containing them |
US6166027A (en) | 1996-10-14 | 2000-12-26 | Bayer Aktiengesellschaft | Heterocyclylmethyl-substituted pyrazole derivatives and their use for treating cardiovascular diseases |
US6180656B1 (en) | 1996-10-14 | 2001-01-30 | Bayer Aktiengesellschaft | Use of condensated (hetaryl-substituted) 1-benzal-3-pyrazol derivates for treating special diseases of the cardiovascular and the central nervous systems |
US6362178B1 (en) | 1997-11-12 | 2002-03-26 | Bayer Aktiengesellschaft | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
US6451805B1 (en) | 1997-11-14 | 2002-09-17 | Bayer Aktiengesellschaft | Substituted pyrazole derivatives for the treatment of cardiocirculatory diseases |
US6469012B1 (en) | 1993-06-09 | 2002-10-22 | Pfizer Inc | Pyrazolopyrimidinones for the treatment of impotence |
US6576651B2 (en) | 2001-01-25 | 2003-06-10 | Bristol-Myers Squibb Company | Pharmaceutical compositions, dosage forms and methods for oral administration of epothilones |
WO2003076408A2 (en) | 2002-03-08 | 2003-09-18 | Abbott Laboratories | Indazole derivatives that are activators of soluble guanylate cyclase |
US6693102B2 (en) | 2000-11-22 | 2004-02-17 | Bayer Aktiengesellschaft | Pyridine-substituted pyrazolopyridine derivatives |
WO2004031187A1 (en) | 2002-09-16 | 2004-04-15 | Bayer Healthcare Ag | Pyridine-substituted pyrazolopyridine derivative |
US6743798B1 (en) | 1998-07-29 | 2004-06-01 | Bayer Aktiengesellschaft | Substituted pyrazole derivatives condensed with six-membered heterocyclic rings |
US6784179B2 (en) | 1994-01-21 | 2004-08-31 | Icos Corporation | Tetracyclic derivatives, process of preparation and use |
US20040235863A1 (en) | 2001-07-04 | 2004-11-25 | Achim Feurer | Morpholine-bridged pyrazolopyridine derivatives |
US6833364B1 (en) | 1998-07-29 | 2004-12-21 | Bayer Healthcare Ag | Substituted pyrazole derivatives |
CN1613849A (en) | 2003-11-03 | 2005-05-11 | 上海药明康德新药开发有限公司 | Preparation of 2-Cl-5-F-nicotinate and nicotonic acid |
US6903089B1 (en) | 2000-11-22 | 2005-06-07 | Bayer Aktiengesellschaft | Lactam-substituted pyrazolopyridine derivatives |
US6919345B2 (en) | 2001-05-11 | 2005-07-19 | Bayer Aktiengesellschaft | Sulfonate substituted pyrazol pyridine derivatives |
CA2577420A1 (en) | 2004-08-20 | 2006-03-02 | University Of Kansas | Lonidamine analogues and their use in male contraception and cancer treatment |
US20060167016A1 (en) | 2002-07-18 | 2006-07-27 | Achim Feurer | 2,5-disubstituted pyrimidine derivatives |
US7105523B2 (en) | 2000-11-22 | 2006-09-12 | Bayer Aktiengeselischaft | Carbamate-substituted pyrazolopyridine-derivatives |
US7115599B2 (en) | 2000-11-22 | 2006-10-03 | Bayer Aktiengesellschaft | Sulfonamide-substituted pyrazolopyridine compounds |
US7135474B2 (en) | 2002-05-17 | 2006-11-14 | Bayer Healthcare Ag | Derivatives of 2-(1-benzyl-1H-pyrazolo(3,4-B)pyridine-3-yl)-5(-4-pyridinyl)l-4-pyrimidinamines and the use thereof as quanylate cyclase stimulators |
US20070015841A1 (en) | 2002-02-15 | 2007-01-18 | Transform Pharmaceuticals, Inc. | Pharmaceutical propylene glycol solvate compositions |
WO2007009607A1 (en) | 2005-07-18 | 2007-01-25 | Bayer Healthcare Ag | Novel use of activators and stimulators of soluble guanylate cyclase for the prevention or treatment of renal disorders |
US7173037B2 (en) | 2002-05-08 | 2007-02-06 | Bayer Healthcare Ag | Carbamate-substituted pyrazolopyridines |
US7176220B2 (en) | 2002-11-20 | 2007-02-13 | Japan Tobacco Inc. | 4-oxoquinoline compound and use thereof as pharmaceutical agent |
US20070072924A1 (en) | 2003-10-31 | 2007-03-29 | Graeme Semple | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof |
US7226941B2 (en) | 2003-06-30 | 2007-06-05 | Hif Bio, Inc. | Compound for treating angiogenesis |
US20070213332A1 (en) | 2004-02-20 | 2007-09-13 | Frank Burkamp | Prodrugs Of Substituted Amino Heterobicycles Which Modulate The Function Of The Vanilloid-1 Receptor (Vr1) |
US20070225299A1 (en) | 2003-11-06 | 2007-09-27 | Bayer Healthcare Ag | Novel Combination Containing a Stimulator of Soluble Guanylate Cyclase and a Lipid-Lowering Substance |
US20080138444A1 (en) | 2004-10-05 | 2008-06-12 | Bayer Healthcare Ag | Method For Treating Bronchoconstriction and Pulmonary Vaso-Constriction |
US7410973B2 (en) | 2002-07-18 | 2008-08-12 | Bayer Healthcare Ag | 4-amino-substituted pyrimidine derivatives |
US7427617B2 (en) | 2002-09-26 | 2008-09-23 | Bayer Healthcare Ag | Morpoline-bridged indazole derivatives |
WO2009000832A2 (en) | 2007-06-25 | 2008-12-31 | Boehringer Ingelheim International Gmbh | Chemical compounds |
US20090215769A1 (en) | 2005-07-16 | 2009-08-27 | Bayer Healthcare Ag | Use of soluble guanylate cyclase activators for the treatment of Raynaud's Phenomenon |
US7666867B2 (en) | 2001-10-26 | 2010-02-23 | University Of Connecticut | Heteroindanes: a new class of potent cannabimimetic ligands |
US20100113507A1 (en) | 2006-05-09 | 2010-05-06 | Bayer Healthcare Ag | 3-Tetrazolyl Indazoles, 3-Tetrazolyl Pyrazolopyridines, and use Thereof |
US7790761B2 (en) | 2000-02-04 | 2010-09-07 | University College London | Blockade of voltage dependent sodium channels |
US20110183999A1 (en) | 2009-11-27 | 2011-07-28 | Bayer Schering Pharma Aktiengesellschaft | Novel polymorphic forms of methyl carbamate |
US20110224197A1 (en) | 2008-03-10 | 2011-09-15 | Vertex Pharmaceuticals Incorporated | Pyrimidines and pyridines useful as inhibitors of protein kinases |
US20120029002A1 (en) | 2009-01-09 | 2012-02-02 | Bayer Schering Pharma Aktiengesellschaft | Benzimidazole and pyrazolopyridine derivatives for treating and/or preventing cardiovascular diseases |
CA2809911A1 (en) | 2010-09-03 | 2012-03-08 | Markus Follmann | Bicyclic aza heterocycles, and use thereof |
US8242272B2 (en) | 2007-07-31 | 2012-08-14 | Vertex Pharmaceuticals Inc. | Process for preparing 5-fluoro-1H-pyrazolo [3,4-B] pyridin-3-amine and derivatives thereof |
US8309551B2 (en) | 2006-09-15 | 2012-11-13 | Bayer Intellectual Property Gmbh | Pyrazolopyridine, indazole, imidazopyridine, imidazopyrimidine, pyrazolopyrazine and pyrazolopyridine derivatives as stimulators of guanylate cyclase for cardiovascular disorders |
US20120309724A1 (en) | 2011-05-31 | 2012-12-06 | Theravance, Inc. | Neprilysin inhibitors |
US8334291B2 (en) | 2008-12-19 | 2012-12-18 | Bayer Intellectual Property Gmbh | Aliphatically substituted pyrazolopyridines, and the use thereof |
US20130053393A1 (en) | 2009-12-18 | 2013-02-28 | Exodos Life Sciences Limited Partnership | Methods and compositions for treating peripheral vascular disease |
US8420656B2 (en) | 2010-05-26 | 2013-04-16 | Bayer Intellectual Property Gmbh | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
US20130178475A1 (en) | 2010-03-17 | 2013-07-11 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
US8492544B2 (en) | 2009-11-27 | 2013-07-23 | Bayer Intellectual Property Gmbh | Process for preparing methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-B]pyridin-3-yl]pyrimidin-5-yl}Methylcarbamate and its purification for use as pharmaceutically active compound |
US8501945B2 (en) | 2009-11-27 | 2013-08-06 | Bayer Intellectual Property Gmbh | Process for preparing methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate and its purification for use as pharmaceutically active compound |
US20130211090A1 (en) | 2010-09-03 | 2013-08-15 | Bayer Intellectual Property Gmbh | Method for the production of 5-fluoro-1h-pyrazolo[3,4-b]pyridine-3-carbonitrile |
US20130267548A1 (en) | 2010-11-04 | 2013-10-10 | Bayer Intellectual Property Gmbh | Substituted 6-fluoro-1h-pyrazolo[4,3-b]pyridines and use thereof |
US8802847B2 (en) | 2011-11-25 | 2014-08-12 | Bayer Intellectual Property Gmbh | Process for preparing substituted 5-fluoro-1H-pyrazolopyridines |
US8859569B2 (en) | 2011-09-02 | 2014-10-14 | Bayer Pharma Aktiengesellschaft | Substituted annellated pyrimidines and use thereof |
US8927557B2 (en) | 2009-08-26 | 2015-01-06 | Takeda Gmbh | Methylpyrrolopyrimidinecarboxamides |
US20150065533A1 (en) | 2010-11-04 | 2015-03-05 | Bayer Intellectual Property Gmbh | Benzyl-substituted carbamates and use thereof |
US9023849B2 (en) | 2012-01-11 | 2015-05-05 | Bayer Intellectual Property Gmbh | Substituted fused imidazoles and pyrazoles and use thereof |
US9216978B2 (en) | 2010-07-09 | 2015-12-22 | Bayer Intellectual Property Gmbh | Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases |
US9365574B2 (en) | 2010-05-27 | 2016-06-14 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01198481A (en) * | 1988-02-01 | 1989-08-10 | Canon Inc | Formation of deposited film by microwave plasma cvd |
GR1004350B (en) * | 2002-03-29 | 2003-09-26 | Inhaler for dry powder | |
EP1626045B1 (en) | 2003-05-09 | 2010-09-08 | Asahi Glass Company, Limited | Processes for producing 3-substituted 2-chloro-5-fluoropyridine or salt thereof |
RS54261B1 (en) * | 2010-05-26 | 2016-02-29 | Adverio Pharma Gmbh | The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of systemic sclerosis (ssc) |
-
2010
- 2010-05-26 DE DE102010021637A patent/DE102010021637A1/en not_active Withdrawn
-
2011
- 2011-05-19 US US13/111,856 patent/US8420656B2/en active Active
- 2011-05-19 UY UY0001033396A patent/UY33396A/en active IP Right Grant
- 2011-05-24 BR BR112012030010-5A patent/BR112012030010A2/en not_active Application Discontinuation
- 2011-05-24 PE PE2012002172A patent/PE20130402A1/en active IP Right Grant
- 2011-05-24 CA CA2800697A patent/CA2800697C/en active Active
- 2011-05-24 EA EA201291336A patent/EA023631B9/en not_active IP Right Cessation
- 2011-05-24 SG SG2012082152A patent/SG185460A1/en unknown
- 2011-05-24 EP EP11720806.6A patent/EP2576547B1/en active Active
- 2011-05-24 RS RS20160263A patent/RS54704B1/en unknown
- 2011-05-24 HU HUE11720806A patent/HUE026912T2/en unknown
- 2011-05-24 MY MYPI2012700999A patent/MY164356A/en unknown
- 2011-05-24 CN CN201180026010.7A patent/CN102939289B/en active Active
- 2011-05-24 ES ES11720806.6T patent/ES2567795T3/en active Active
- 2011-05-24 ME MEP-2016-64A patent/ME02393B/en unknown
- 2011-05-24 SI SI201130781A patent/SI2576547T1/en unknown
- 2011-05-24 DK DK11720806.6T patent/DK2576547T3/en active
- 2011-05-24 KR KR1020127033601A patent/KR101862420B1/en active IP Right Grant
- 2011-05-24 MA MA35391A patent/MA34248B1/en unknown
- 2011-05-24 MX MX2012013324A patent/MX2012013324A/en active IP Right Grant
- 2011-05-24 BR BR122020023470-9A patent/BR122020023470B1/en active IP Right Grant
- 2011-05-24 NZ NZ603800A patent/NZ603800A/en unknown
- 2011-05-24 UA UAA201214902A patent/UA109660C2/en unknown
- 2011-05-24 CU CU2012000161A patent/CU24086B1/en active IP Right Grant
- 2011-05-24 AU AU2011257335A patent/AU2011257335B2/en active Active
- 2011-05-24 PL PL11720806T patent/PL2576547T3/en unknown
- 2011-05-24 WO PCT/EP2011/058431 patent/WO2011147809A1/en active Application Filing
- 2011-05-24 JP JP2013511643A patent/JP5896991B2/en active Active
- 2011-05-24 AR ARP110101777A patent/AR081628A1/en active IP Right Grant
- 2011-05-24 JO JOP/2011/0171A patent/JO3199B1/en active
- 2011-05-25 TW TW100118222A patent/TWI516263B/en active
-
2012
- 2012-11-15 IL IL223050A patent/IL223050A/en active IP Right Grant
- 2012-11-16 CO CO12208156A patent/CO6640226A2/en active IP Right Grant
- 2012-11-20 CL CL2012003226A patent/CL2012003226A1/en unknown
- 2012-11-21 GT GT201200313A patent/GT201200313A/en unknown
- 2012-11-23 DO DO2012000299A patent/DOP2012000299A/en unknown
- 2012-11-23 TN TNP2012000549A patent/TN2012000549A1/en unknown
- 2012-11-26 CR CR20120596A patent/CR20120596A/en unknown
- 2012-11-26 EC ECSP12012310 patent/ECSP12012310A/en unknown
-
2013
- 2013-03-27 US US13/851,373 patent/US8921377B2/en active Active
- 2013-08-15 HK HK13109548.3A patent/HK1182112A1/en unknown
-
2014
- 2014-11-24 US US14/552,122 patent/US9266885B2/en active Active
-
2016
- 2016-01-15 US US14/996,678 patent/US20160129004A1/en not_active Abandoned
- 2016-04-11 HR HRP20160370TT patent/HRP20160370T1/en unknown
- 2016-04-12 CY CY20161100301T patent/CY1117372T1/en unknown
- 2016-11-10 US US15/348,545 patent/US9993476B2/en active Active
- 2016-12-20 IL IL249669A patent/IL249669B/en active IP Right Grant
-
2018
- 2018-05-16 US US15/981,598 patent/US10736896B2/en active Active
-
2020
- 2020-07-02 US US16/919,385 patent/US11439642B2/en active Active
-
2021
- 2021-08-26 LT LTPA2021518C patent/LTC2576547I2/lt unknown
- 2021-08-27 HU HUS2100032C patent/HUS2100032I1/en unknown
- 2021-08-30 FR FR21C1038C patent/FR21C1038I2/en active Active
- 2021-09-06 NO NO2021032C patent/NO2021032I1/en unknown
- 2021-12-01 NL NL301146C patent/NL301146I2/en unknown
-
2022
- 2022-08-18 US US17/820,667 patent/US20220409618A1/en active Pending
Patent Citations (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0463756A1 (en) | 1990-06-20 | 1992-01-02 | Pfizer Limited | Pyrazolopyrimidinone antianginal agents |
EP0463754A1 (en) | 1990-06-25 | 1992-01-02 | Rohm And Haas Company | Stabilization of glutarimide polymers |
US5393761A (en) | 1990-07-30 | 1995-02-28 | H. Lundbeck A/S | 3-arylindole compounds |
US6469012B1 (en) | 1993-06-09 | 2002-10-22 | Pfizer Inc | Pyrazolopyrimidinones for the treatment of impotence |
CA2127624A1 (en) | 1993-07-13 | 1995-01-14 | Barry D. G. Haylor | Herbicides |
EP0634413A1 (en) | 1993-07-13 | 1995-01-18 | Rhone Poulenc Agriculture Ltd. | Herbicides |
US6784179B2 (en) | 1994-01-21 | 2004-08-31 | Icos Corporation | Tetracyclic derivatives, process of preparation and use |
US6166027A (en) | 1996-10-14 | 2000-12-26 | Bayer Aktiengesellschaft | Heterocyclylmethyl-substituted pyrazole derivatives and their use for treating cardiovascular diseases |
US6180656B1 (en) | 1996-10-14 | 2001-01-30 | Bayer Aktiengesellschaft | Use of condensated (hetaryl-substituted) 1-benzal-3-pyrazol derivates for treating special diseases of the cardiovascular and the central nervous systems |
US6008243A (en) | 1996-10-24 | 1999-12-28 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use |
US6090818A (en) | 1996-12-13 | 2000-07-18 | Sanofi-Synthelabo | Indolin-2-one derivatives, method for preparing them and pharmaceutical compositions containing them |
US6362178B1 (en) | 1997-11-12 | 2002-03-26 | Bayer Aktiengesellschaft | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
US6451805B1 (en) | 1997-11-14 | 2002-09-17 | Bayer Aktiengesellschaft | Substituted pyrazole derivatives for the treatment of cardiocirculatory diseases |
WO2000006567A1 (en) | 1998-07-29 | 2000-02-10 | Bayer Aktiengesellschaft | 3-(4-amino-5-ethylpyrimidine-2-yl)-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridine |
US6743798B1 (en) | 1998-07-29 | 2004-06-01 | Bayer Aktiengesellschaft | Substituted pyrazole derivatives condensed with six-membered heterocyclic rings |
US6833364B1 (en) | 1998-07-29 | 2004-12-21 | Bayer Healthcare Ag | Substituted pyrazole derivatives |
CA2346698A1 (en) | 1998-10-09 | 2000-04-20 | Bayer Aktiengesellschaft | Novel heterocyclyl-methyl-substituted pyrazoles |
WO2000021954A1 (en) | 1998-10-09 | 2000-04-20 | Bayer Aktiengesellschaft | Novel heterocyclyl-methyl-substituted pyrazoles |
US7790761B2 (en) | 2000-02-04 | 2010-09-07 | University College London | Blockade of voltage dependent sodium channels |
US6693102B2 (en) | 2000-11-22 | 2004-02-17 | Bayer Aktiengesellschaft | Pyridine-substituted pyrazolopyridine derivatives |
US7105523B2 (en) | 2000-11-22 | 2006-09-12 | Bayer Aktiengeselischaft | Carbamate-substituted pyrazolopyridine-derivatives |
US6903089B1 (en) | 2000-11-22 | 2005-06-07 | Bayer Aktiengesellschaft | Lactam-substituted pyrazolopyridine derivatives |
US7115599B2 (en) | 2000-11-22 | 2006-10-03 | Bayer Aktiengesellschaft | Sulfonamide-substituted pyrazolopyridine compounds |
US6576651B2 (en) | 2001-01-25 | 2003-06-10 | Bristol-Myers Squibb Company | Pharmaceutical compositions, dosage forms and methods for oral administration of epothilones |
US6919345B2 (en) | 2001-05-11 | 2005-07-19 | Bayer Aktiengesellschaft | Sulfonate substituted pyrazol pyridine derivatives |
US20040235863A1 (en) | 2001-07-04 | 2004-11-25 | Achim Feurer | Morpholine-bridged pyrazolopyridine derivatives |
US7666867B2 (en) | 2001-10-26 | 2010-02-23 | University Of Connecticut | Heteroindanes: a new class of potent cannabimimetic ligands |
US20070015841A1 (en) | 2002-02-15 | 2007-01-18 | Transform Pharmaceuticals, Inc. | Pharmaceutical propylene glycol solvate compositions |
US7790905B2 (en) | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
WO2003076408A2 (en) | 2002-03-08 | 2003-09-18 | Abbott Laboratories | Indazole derivatives that are activators of soluble guanylate cyclase |
US7173037B2 (en) | 2002-05-08 | 2007-02-06 | Bayer Healthcare Ag | Carbamate-substituted pyrazolopyridines |
US7135474B2 (en) | 2002-05-17 | 2006-11-14 | Bayer Healthcare Ag | Derivatives of 2-(1-benzyl-1H-pyrazolo(3,4-B)pyridine-3-yl)-5(-4-pyridinyl)l-4-pyrimidinamines and the use thereof as quanylate cyclase stimulators |
US7091198B1 (en) | 2002-07-18 | 2006-08-15 | Bayer Healthcare Ag | 2,5-disubstituted pyrimidine derivatives |
US20060167016A1 (en) | 2002-07-18 | 2006-07-27 | Achim Feurer | 2,5-disubstituted pyrimidine derivatives |
US7410973B2 (en) | 2002-07-18 | 2008-08-12 | Bayer Healthcare Ag | 4-amino-substituted pyrimidine derivatives |
WO2004031187A1 (en) | 2002-09-16 | 2004-04-15 | Bayer Healthcare Ag | Pyridine-substituted pyrazolopyridine derivative |
US7427617B2 (en) | 2002-09-26 | 2008-09-23 | Bayer Healthcare Ag | Morpoline-bridged indazole derivatives |
US7176220B2 (en) | 2002-11-20 | 2007-02-13 | Japan Tobacco Inc. | 4-oxoquinoline compound and use thereof as pharmaceutical agent |
US7226941B2 (en) | 2003-06-30 | 2007-06-05 | Hif Bio, Inc. | Compound for treating angiogenesis |
US20070072924A1 (en) | 2003-10-31 | 2007-03-29 | Graeme Semple | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof |
CN1613849A (en) | 2003-11-03 | 2005-05-11 | 上海药明康德新药开发有限公司 | Preparation of 2-Cl-5-F-nicotinate and nicotonic acid |
US20070225299A1 (en) | 2003-11-06 | 2007-09-27 | Bayer Healthcare Ag | Novel Combination Containing a Stimulator of Soluble Guanylate Cyclase and a Lipid-Lowering Substance |
US20070213332A1 (en) | 2004-02-20 | 2007-09-13 | Frank Burkamp | Prodrugs Of Substituted Amino Heterobicycles Which Modulate The Function Of The Vanilloid-1 Receptor (Vr1) |
US7514463B2 (en) | 2004-08-20 | 2009-04-07 | University Of Kansas | Lonidamine analogues and their use in male contraception and cancer treatment |
CA2577420A1 (en) | 2004-08-20 | 2006-03-02 | University Of Kansas | Lonidamine analogues and their use in male contraception and cancer treatment |
US20080138444A1 (en) | 2004-10-05 | 2008-06-12 | Bayer Healthcare Ag | Method For Treating Bronchoconstriction and Pulmonary Vaso-Constriction |
US20090215769A1 (en) | 2005-07-16 | 2009-08-27 | Bayer Healthcare Ag | Use of soluble guanylate cyclase activators for the treatment of Raynaud's Phenomenon |
WO2007009607A1 (en) | 2005-07-18 | 2007-01-25 | Bayer Healthcare Ag | Novel use of activators and stimulators of soluble guanylate cyclase for the prevention or treatment of renal disorders |
US20100113507A1 (en) | 2006-05-09 | 2010-05-06 | Bayer Healthcare Ag | 3-Tetrazolyl Indazoles, 3-Tetrazolyl Pyrazolopyridines, and use Thereof |
US8309551B2 (en) | 2006-09-15 | 2012-11-13 | Bayer Intellectual Property Gmbh | Pyrazolopyridine, indazole, imidazopyridine, imidazopyrimidine, pyrazolopyrazine and pyrazolopyridine derivatives as stimulators of guanylate cyclase for cardiovascular disorders |
WO2009000832A2 (en) | 2007-06-25 | 2008-12-31 | Boehringer Ingelheim International Gmbh | Chemical compounds |
US8242272B2 (en) | 2007-07-31 | 2012-08-14 | Vertex Pharmaceuticals Inc. | Process for preparing 5-fluoro-1H-pyrazolo [3,4-B] pyridin-3-amine and derivatives thereof |
US20110224197A1 (en) | 2008-03-10 | 2011-09-15 | Vertex Pharmaceuticals Incorporated | Pyrimidines and pyridines useful as inhibitors of protein kinases |
US8334291B2 (en) | 2008-12-19 | 2012-12-18 | Bayer Intellectual Property Gmbh | Aliphatically substituted pyrazolopyridines, and the use thereof |
US20120029002A1 (en) | 2009-01-09 | 2012-02-02 | Bayer Schering Pharma Aktiengesellschaft | Benzimidazole and pyrazolopyridine derivatives for treating and/or preventing cardiovascular diseases |
US8927557B2 (en) | 2009-08-26 | 2015-01-06 | Takeda Gmbh | Methylpyrrolopyrimidinecarboxamides |
US8492544B2 (en) | 2009-11-27 | 2013-07-23 | Bayer Intellectual Property Gmbh | Process for preparing methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-B]pyridin-3-yl]pyrimidin-5-yl}Methylcarbamate and its purification for use as pharmaceutically active compound |
US8853398B2 (en) | 2009-11-27 | 2014-10-07 | Bayer Intellectual Property Gmbh | Process for preparing methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b] pyridin-3-yl]pyrimidin-5-yl}methylcarbamate and its purification for use as pharmaceutically active compound |
US8501945B2 (en) | 2009-11-27 | 2013-08-06 | Bayer Intellectual Property Gmbh | Process for preparing methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate and its purification for use as pharmaceutically active compound |
US20110183999A1 (en) | 2009-11-27 | 2011-07-28 | Bayer Schering Pharma Aktiengesellschaft | Novel polymorphic forms of methyl carbamate |
US20130053393A1 (en) | 2009-12-18 | 2013-02-28 | Exodos Life Sciences Limited Partnership | Methods and compositions for treating peripheral vascular disease |
US20130178475A1 (en) | 2010-03-17 | 2013-07-11 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
US8921377B2 (en) | 2010-05-26 | 2014-12-30 | Bayer Intellectual Property Gmbh | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
US9993476B2 (en) * | 2010-05-26 | 2018-06-12 | Adverio Pharma Gmbh | Substituted 5-flouro-1H-pyrazolopyridines and their use |
US9266885B2 (en) | 2010-05-26 | 2016-02-23 | Adverio Pharma Gmbh | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
US8420656B2 (en) | 2010-05-26 | 2013-04-16 | Bayer Intellectual Property Gmbh | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
US9365574B2 (en) | 2010-05-27 | 2016-06-14 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
US9216978B2 (en) | 2010-07-09 | 2015-12-22 | Bayer Intellectual Property Gmbh | Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases |
US9096592B2 (en) | 2010-09-03 | 2015-08-04 | Bayer Intellectual Property Gmbh | Bicyclic aza heterocycles, and use thereof |
CA2809911A1 (en) | 2010-09-03 | 2012-03-08 | Markus Follmann | Bicyclic aza heterocycles, and use thereof |
US20130211090A1 (en) | 2010-09-03 | 2013-08-15 | Bayer Intellectual Property Gmbh | Method for the production of 5-fluoro-1h-pyrazolo[3,4-b]pyridine-3-carbonitrile |
US20150065533A1 (en) | 2010-11-04 | 2015-03-05 | Bayer Intellectual Property Gmbh | Benzyl-substituted carbamates and use thereof |
US9090609B2 (en) | 2010-11-04 | 2015-07-28 | Bayer Intellectual Property Gmbh | Benzyl-substituted carbamates and use thereof |
US20130267548A1 (en) | 2010-11-04 | 2013-10-10 | Bayer Intellectual Property Gmbh | Substituted 6-fluoro-1h-pyrazolo[4,3-b]pyridines and use thereof |
US20120309724A1 (en) | 2011-05-31 | 2012-12-06 | Theravance, Inc. | Neprilysin inhibitors |
US8859569B2 (en) | 2011-09-02 | 2014-10-14 | Bayer Pharma Aktiengesellschaft | Substituted annellated pyrimidines and use thereof |
US20140315926A1 (en) | 2011-11-25 | 2014-10-23 | Bayer Intellectual Property Gmbh | Process for preparing substituted 5-fluoro-1H-pyrazolopyridines |
US9150573B2 (en) | 2011-11-25 | 2015-10-06 | Adverio Pharma Gmbh | Process for preparing substituted 5-fluoro-1H-pyrazolopyridines |
US8802847B2 (en) | 2011-11-25 | 2014-08-12 | Bayer Intellectual Property Gmbh | Process for preparing substituted 5-fluoro-1H-pyrazolopyridines |
US9023849B2 (en) | 2012-01-11 | 2015-05-05 | Bayer Intellectual Property Gmbh | Substituted fused imidazoles and pyrazoles and use thereof |
Non-Patent Citations (66)
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11439642B2 (en) | Substituted 5-fluoro-1H-pyrazolopyridines and their use | |
US9309239B2 (en) | Substituted 6-fluoro-1H-pyrazolo[4,3-b]pyridines and use thereof | |
US9266871B2 (en) | Trifluoromethyl-substituted fused pyrimidines and their use | |
US8765769B2 (en) | Ring-fused 4-aminopyrimidines and use thereof as stimulators of soluable guanylate cyclases | |
US9090610B2 (en) | Fluoroalkyl-substituted pyrazolopyridines and use thereof | |
US9498480B2 (en) | Substituted azabicycles and use thereof | |
US9133191B2 (en) | Substituted triazine derivatives and use thereof as stimulators of soluble guanylate cyclase | |
US20140228366A1 (en) | Heteroaryl-substituted pyrazolopyridines and use thereof as soluble guanylate cyclase stimulators | |
US9605008B2 (en) | Benzyl-1H-pyrazolo[3,4-b]pyridines and use thereof | |
US9150580B2 (en) | Substituted imidazopyridines and the use thereof | |
US20140128425A1 (en) | Carboxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use | |
CA2902987A1 (en) | Benzyl-substituted pyrazolopyridines and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: BAYER PHARMA AKTIENGESELLSCHAFT, GERMANY Free format text: CHANGE OF NAME;ASSIGNOR:BAYER SCHERING PHARMA AKTIENGESELLSCHAFT;REEL/FRAME:055222/0814 Effective date: 20110701 Owner name: ADVERIO PHARMA GMBH, GERMANY Free format text: NUNC PRO TUNC ASSIGNMENT;ASSIGNOR:BAYER INTELLECTUAL PROPERTY GMBH;REEL/FRAME:055152/0361 Effective date: 20141223 Owner name: BAYER INTELLECTUAL PROPERTY GMBH, GERMANY Free format text: NUNC PRO TUNC ASSIGNMENT;ASSIGNOR:BAYER PHARMA AKTIENGESELLSCHAFT;REEL/FRAME:055152/0031 Effective date: 20120401 Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FOLLMANN, MARKUS;STASCH, JOHANNES-PETER;REDLICH, GORDEN;AND OTHERS;SIGNING DATES FROM 20110606 TO 20110620;REEL/FRAME:055151/0491 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |